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Abstract 
 
Introduction: Immunosuppressive agents are commonly used in Systemic Lupus 
Erythematous (SLE) during pregnancy, to ensure optimum outcome for both mother and 
child. However there is little literature regarding long term outcomes (LTO) of these 
children.  
Aims: This pilot study aims to test the hypothesis that the mother’s medications taken 
during pregnancy and/or antibodies are associated with an increased risk of adverse 
outcomes in children born to mothers with lupus.  
 
Methods: Women regularly attending specialist UK lupus clinics were identified and 
consented to take part in this study if they had children up to the age of 17 years born after 
the diagnosis of SLE. A standard questionnaire developed for this multi-centre study was 
used to collect the data.  
 
Results: In total data were collected for 285 children born to 199 mothers. Neonatal rash, 
complete heart block or congenital anomalies were each reported in 2% of children, and 
developmental problems in 17/284(6%). Hospital management was required for infection 
in 25% (69/274) of children, the only significant risk factors identified were birth weight 
and maternal aspirin use which are likely to be surrogate markers for more severe maternal 
disease.  
 
Conclusion: This study demonstrated reassuring LTO of children born to mothers with 
SLE. 
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Introduction  
a. What is SLE? 
Systemic lupus erythematous (SLE) is a multisystem, autoimmune disease, which can 
cause constitutional or organ-specific symptoms. Any part of the body can be affected, 
including the skin, mucous membranes, joints, kidney, peripheral and central nervous 
system, serous membranes, lung, heart, lymph nodes, genital tract and occasionally the 
gastrointestinal tract may all be involved(1;2).  SLE is an autoantibody-mediated disease 
with immune complex formation and complement activation which results in organ 
inflammation. 
 
b. Who gets SLE? 
SLE has a prevalence of around 73 cases per 100,000, which is higher in those of African 
American or Indian descent, predominantly affecting women of childbearing age (15–55 
years) the female: male ratio peak is 12:1 (3-6).  
 SLE is more common in non-Caucasians, black patients are younger at diagnosis, in 
addition to having a greater than 2 fold increase in incidence and prevalence (1-3;5). Lupus 
disease is also more severe in non-Caucasians, studies have identified that there is a higher 
proportion of renal disease and progression to end stage renal disease (ESRD) (1-3;7).  
 
 
c. What are the manifestations?  
The incidence of significant features of SLE are summarised in Table 2. Arthritis in SLE 
can be divided into a deforming and non-deforming arthropathy. Constitutional symptoms 
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consist of fever, malaise, fatigue, weight loss, lymphadenopathy, and anorexia (1;2). There 
are multiple cutaneous manifestations of lupus: commonly these include photosensitivity 
(>50% of patients), butterfly/malar rash, painful/painless oral ulcers, diffuse alopecia, and 
livedo reticularis (1;2). The effects of SLE on the reproductive system, including fertility 
and pregnancy will be covered later in the pregnancy considerations section.  
Renal disease is one of the most serious SLE manifestations and presents with 
proteinuria, red cells and casts in the urine. Neuropsychiatric SLE (NPSLE) is a major 
diagnostic and treatment problem. The (American College of Rheumatology) ACR has 
provided NPSLE classification criteria, describing central and peripheral types of 
neurological involvement that may be found in lupus patients(2). 
Pulmonary features of SLE include pleurisy, pneumonitis, pulmonary hemorrhage, 
pulmonary embolism, pulmonary hypertension, and diaphragmatic weakness causing 
shrinking lungs. Pericarditis is the most common cardiological manifestation; others 
include myocarditis, endocarditis, accelerated atherosclerosis, and, rarely, pericardial 
tamponade(2). Abdominal pain, nausea, vomiting, and diarrhea occur in up to 50% of SLE 
patients. Gastrointestinal involvement includes mesenteric vasculitis (high risk of death), 
aseptic peritonitis (with or without ascites), subacute bowel obstruction, hepatitis, 
sclerosing cholangitis, protein-losing enteropathy, pancreatitis, and ascites(2). 
Cytopenias, including anemia, leucopoenia or thrombocytopenia, are commonly 
associated with SLE; they may be immune-mediated or due to other factors, e.g. menstrual 
losses. Antiphospholipid antibodies and lupus anticoagulant are found in about 30–40% of 
patients, associated with venous and arterial thrombosis, recurrent fetal loss, pre-eclampsia, 
headache, and epilepsy(2). 
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A firm diagnosis of lupus is made based on appropriate clinical findings and the 
measurement of at least one antibody.  Antibodies are the hallmark of SLE, and (anti-
double-strandedDNA (anti-dsDNA) levels fluctuate with disease activity and are measured 
in clinical practice to assess disease activity. There are a number of antibodies associated 
with SLE, the most common being ANA (antinuclear antibody), which is found in over 
95% of patients. Other associated autoantibodies include anti-dsDNA antibodies in 
approximately 60% of patients, the highly specific anti-Sm antibody (Smith proteins) in 
10–30% of patients, and anti-RNP (ribonucleoprotein) also in 10–30% of patients (2;8). 
Anti-Ro and anti-La antibodies can be seen in approximately 40% of patients (2;9). They 
are associated with Sjogrens syndrome, cutaneous and neonatal lupus and congenital heart 
block(2;9). 
 
 
d. How is it treated 
The treatment of SLE is tailored to the severity of disease. General lifestyle advice 
includes avoidance of sunlight and use of sun block. Patients should have regular disease 
assessments, and be screened for SLE complications, such as infection, diabetes, 
hyperlipidaemia, and hypertension.  
Mild cases with intermittent rashes, arthritis, and other mucocutaneous features can usually 
be treated with corticosteroid creams, short courses of NSAIDs, and hydroxychloroquine 
(<6.5mg/kg/day). More severe cases of SLE usually require oral corticosteroids. Patients 
who need 10mg/day of prednisone or more despite hydroxychloroquine, or those who 
present with more severe manifestations (such as nephritis, gastrointestinal vasculitis or 
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central nervous system disease) that need higher initial doses of prednisone (0.5-
1mg/kg/day) are likely to need azathioprine(AZA), methotrexate, mycophenolate mofetil 
or cyclophosphamide as steroid-sparing immunosuppressive agents. If conservative 
treatment and traditional immunosuppressives fail then biologics should be considered. 
Rituximab is a monoclonal antibody against the B-lymphocyte marker CD20 expressed on 
B cells, it has been used in SLE patients since 2002, and observational studies have 
suggested that rituximab is effective in treating active SLE refractory to standard 
immunosuppressant(10). Recent data have demonstrated that repeated treatment with 
rituximab is effective in treating refractory SLE and has a favourable safety profile (11;12). 
Lightstone and co-workers are currently investigating the possibility of corticosteroid 
avoidance regimes using rituximab at initiation of therapy for lupus nephritis (11;12). 
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Table 2- Cumulative Incidence of SLE Manifestations 
Adapted from Pons-Estel et al (9) 
Manifestations Cumulative Incidence (%) 
Systemic  Fever 57 
 Weight loss 27 
Musculoskeletal 
 
Arthritis & Arthralgia 93 
 Myalgia 18 
Cardiorespiratory Pericarditis 17 
 Pleural Effusion 22 
Cutaneous Alopecia 58 
 Oral/nasal ulcers 42 
 Photosensitivity 56 
 Raynaud 28 
 Discoid Lesions 12 
Neurologic All types Central 
Nervous System 
damage 
26 
 Psychosis 4 
Renal Proteinuria/Abnormal 
sediment 
46 
 Nephrotic Syndrome 7 
Gastrointestinal Ascites 1 
Haematological Lymphadenopathy 15 
 Haemolytic anaemia 12 
 Leucopenia (< 4500 
leucocytes/mL) 
42 
 Thrombocytopenia (< 
100, 000 
19 
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platelets/mL) 
Serological ANA 98 
 Anti-dsDNA 71 
 Anti-Smith 48 
 Anti-Ro 49 
 Anti-RNP 51 
 Anticardiolipin 
IgG/IgM 
51/41 
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Pregnancy considerations 
 
Introduction 
 
 In the past women with SLE were advised against pregnancy due to maternal and fetal 
morbidity and mortality and the complex influence of sex hormones on immunity(13). 
Studies have found that women with SLE have fewer children than they might desire, and 
a reduction in family size has been demonstrated (14-17).  There are many potential factors 
that may influence family size including, physical and psychosocial, which may vary 
depending on current and/or past disease activity, damage, and/or treatment (14-17). There 
are several potential complications women need to be counselled about which include 
miscarriages, stillbirth, preterm birth, intrauterine growth restriction (IUGR), pre-
eclampsia, neonatal lupus and congenital heart block (CHB). These complications are 
discussed in the relevant sections below. 
 
 
Effect of pregnancy on the mother 
 
Possible maternal complications include disease flare, hypertension and pre-eclampsia. 
However in recent years, it has been found that with good disease control and rigorous 
monitoring, there is no reason why the majority of these women should not have the 
opportunity to bear children (13;18). It is recommended that women should have stable 
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disease for a minimum of six months, as active disease is associated with a 3-fold increase 
in pregnancy loss (miscarriages and perinatal mortality)(19). 
 
 
a) Lupus Flare 
Generally the risk of flare is least if disease is well controlled for six months prior to 
pregnancy (19-21). There is no consensus on whether lupus flares increase in pregnancy, 
but historically patients used to stop all their drug therapy when a pregnancy was 
confirmed, which may have led to an increased risk of flare in pregnancy.  Other possible 
explanations for this include the differences in lupus flare definitions, assessment of 
disease activity, and differentiation between lupus flare and pregnancy associated 
complications or physiological changes of pregnancy(22). 
 
b) Pre-eclampsia 
Pre-eclampsia is defined as new hypertension after 20 weeks of pregnancy with significant 
proteinuria (urinary protein: creatinine ratio greater than 30 mg/mmol or 24‑hour urine 
collection result greater than 300 mg protein(23). Advanced maternal age, previous 
personal or family history of pre-eclampsia, pre-existing hypertension or diabetes mellitus 
and obesity, are all pre-disposing factors for pre-eclampsia(24)  
Pre-eclampsia effects 16-30% of SLE pregnancies, the lupus specific associated risk 
factors are; (past or current) hypertension, lupus nephritis, high SLEDAI score and 
antiphospholipid antibodies (25-27).  
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Although pre-eclampsia and lupus nephritis can co-exist in pregnancy, it is essential to 
distinguish the two conditions see Table 3, as steroids are necessary to treat lupus nephritis 
but will aggravate pre-eclampsia. In contrast delivery of the fetus will be the ultimate 
treatment for pre-eclampsia, although anti-hypertensives may be tried initially.  
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Table 3 - Summary of key clinical and serological differences between lupus flare and 
pre-eclampsia  
 Lupus Flare Pre-eclampsia 
Hypertension Anytime in 
pregnancy 
After 20 weeks 
gestation 
Urine analysis Proteinuria 
Red Cell Casts 
Proteinuria 
Platelet Count Low Low 
Abnormal LFTs Unusual Common 
Creatinine Raised Raised 
dsDNA* Raised Normal 
Complement** Low Normal 
Uric Acid Can be raised in the 
presence of CKD 2-
5 
High 
Response to steroids Yes No 
 
*Rising anti-DNA antibodies are the best marker of flare, but only 60% of lupus patients 
make them 
**C3 and C4 usually rise 10-50% in pregnancy, a fall of 25% suggests active disease(28). 
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Effects of maternal Antibodies on pregnancy 
a) Neonatal lupus/congenital heart block 
 
Neonatal lupus syndrome occurs due to the transmission of maternal anti-Ro and/or La 
antibodies across the placenta from week 16. It may present as transient cutaneous lupus 
lesions, complete heart block, cytopenia, hepatic and other manifestations, occurring in 
infants born to mothers with positive anti-Ro or anti-La antibodies (29;30).   
 
IgG antibodies can cross the placenta from approximately 16 week gestation, neonatal 
lupus syndrome occurs in about 5% of mothers (30-33). With the exception of the cardiac 
manifestations of neonatal lupus, the manifestations resolve with the clearance of maternal 
antibodies by the age of 6-8 months (30-33).   
 
Anti-Ro and La antibodies are reported to be present in 40 and 20% of SLE patients 
respectively (34). The presence of anti-Ro/La antibodies is associated with a 5% risk of 
neonatal lupus rash and CHB in about 1-2% of babies, with an increased risk of up to 20% 
of a subsequent child having CHB if a previous child had CHB (33;35-39) .  
 
If complete CHB is identified, mortality in utero or in the first three months has been 
reported to be up to thirty percent, despite intensive care (33). Permanent pacemakers are 
required by 67% of survivors with complete CHB(29). 
 
 Pregnant women with anti-Ro/SSA or anti-La/SSB autoantibodies are closely monitored 
during pregnancy as early identification and prompt treatment with dexamethasone may 
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dampen down myocarditis or cardiac failure, but there is no evidence that it prevents 
development of CHB (38;40;41;41). There is no evidence that plasma exchange or IV 
immunoglobulin will prevent the reoccurrence CHB (42-44).  
 
b) What are the factors that increase the risk of Antiphospholipid Antibodies? 
 
Antiphospholipid antibodies (Lupus Anticoagulant and/or anti-cardiolipin IgG and or IgM) 
antibodies (aPL) are commoner in patients with SLE (30–40%) than the background 
population (1–5%), and are associated with an increased risk of thrombosis(45). Studies 
have found that certain antibodies and/or combinations are associated with a greater risk of 
thrombosis (46).    High risk antibody profiles include: Lupus anticoagulant, triple 
positivity (Lupus anticoagulant and anti-cardiolipin and B2 glycoprotein antibodies) and 
persistently positive anticardiolipin antibodies at medium–high titres (46), whereas an 
isolated, intermittently positive anti-cardiolipin or B2 glycoprotein antibodies at low-
medium titres has been demonstrated to carry a lower risk of thrombosis (46) 
 
 The presence of antiphospholipid antibodies is significant in pregnancy as the following 
adverse pregnancy outcomes have been observed in pregnant SLE women with 
antiphospholipid antibodies: miscarriages, IUGR, pregnancy associated hypertension, 
preterm birth, still birth and small for dates babies(45;47-53). The Euro-phospholipid 
international study, studied a 1000 patients with antiphospholipid syndrome, and identified  
early fetal losses, <10 weeks,  (35.4%), late fetal losses, ≥ 10 weeks (16.9% of the 
pregnancies) and preterm birth (10.6% of live births) and  pre-eclampsia (9.5%)(45). 
Recent data from the European neonatal registry of babies born to mothers with 
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antiphospholipid syndrome found that despite recommended treatment there is still a 
greater risk of the following complications: preterm delivery and IUGR than in general 
population, about which mothers will need to be counselled (52). 
 
 Pregnancy outcomes can be optimised in pregnancy by testing for antiphospholipid 
antibodies prior to pregnancy, so an accurate risk assessment can be made and appropriate 
treatment initiated with low dose aspirin and, if appropriate, low molecular weight 
heparin(51;54). These pregnancies will need to be closely managed by an obstetrician and 
medical team (haematologist and/or Rheumatologist), to monitor and treat any pregnancy 
complications, which will increase the chance of a good pregnancy outcome to up to 75-
80% (51;54).  
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Effects of SLE on the baby 
 
There is a wealth of clinical experience and expert opinion, on the management of SLE in 
pregnancy, and what drug treatment is considered suitable. The multiple studies which 
have looked at the short term outcomes, normally only address the first few months of life. 
Studies performed on the obstetric (short term) outcomes have identified several risk 
factors for adverse events, and these form the basis of pre-pregnancy counselling and 
current practice  
 
 
a) Miscarriages/still birth? 
The risk of fetal loss has significantly decreased in pregnancies in patients with SLE, from 
43% before 1975 to 17% in 2000–2003(55).  
 
Antiphospholipid antibodies (Lupus Anticoagulant and/or anti-cardiolipin IgG and or IgM) 
are common in SLE patients, and are associated with an increased risk of miscarriages and 
still birth (13;47;53;56). A higher rate of adverse obstetric outcomes, including 
miscarriages and still birth have also been demonstrated in women with SLE and 
hypertension(13). Disease activity as indicated by hypocomplementaemia, lupus nephritis 
and high disease activity in the six months prior to conception is associated with an 
increase in miscarriages and still birth (20;48;53;57-62). Other predictors include the 
presence of thrombocytopenia, proteinuria and hypertension (20;63). 
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b) Small for dates/IUGR 
 IUGR is defined as a foetus that has failed to achieve their growth potential, and their 
estimated fetal growth below the 10 the percentile for gestational age.(64) There is a three-
fold higher rate of IUGR, in pregnancies complicated by both SLE and hypertension 
(13;65). Nearly 25% of pregnancies in women with SLE are complicated by hypertensive 
disorders (65). The risk of IUGR is increased in those with active disease at conception and 
in those with anti-phospholipid antibodies (53;60;63;66;67). Low birth weight (<2.5kg), is 
either due to IUGR, prematurity or both, and is associated with increased neonatal 
morbidity and mortality(68).  
 
 
Small for dates is defined as a foetal  birth weight below the tenth percentile of that 
population for sex and gestational age at delivery(69).  Small for dates babies are 
significantly more frequent among SLE patients with renal disease compared to non-renal 
patients (25;53;63;67). 
 
c) Preterm birth 
 
Preterm delivery, which is defined as occurring before 37 weeks of gestation, is commoner 
in lupus, than in the general population (52). Varying rates of preterm delivery have been 
reported in the literature, a meta-analysis reported a 39.4% rate in lupus patients (53). 
Preterm delivery can be spontaneous, but is more often due to induction or emergency 
caesarean section due to another complication e.g. IUGR and/or fetal distress.  
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Several risk factors have been identified to be associated with preterm delivery in the 
literature, these include the presence of lupus nephritis and active disease during pregnancy 
[19, 28, 57, 53]. The presence of antiphospholipid antibodies has been linked with preterm 
delivery in several studies [19, 54]. Hypertension during pregnancy is also associated with 
IUGR and preterm delivery, and should be appropriately treated prior to and during 
pregnancy [18]. 
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Effect of medications on pregnancy? 
 
It is essential to ensure good disease control throughout pregnancy, as active disease during 
pregnancy can result in adverse outcomes for both mother and child as described above: 
including reduced live births, earlier deliveries, pregnancy loss and small for gestational 
age babies(19;20;55;60) This often necessitates the use of disease modifying therapy to 
allow the disease process to be brought under control, and so pregnancy can be achieved 
and maintained to term. 
 
Drugs to be stopped 
Certain medications, including mycophenolate mofetil, cyclophosphamide and 
methotrexate used in the treatment of lupus are known to be teratogenic, and as a 
consequence are not recommended. There are several case reports in the literature that 
have attributed congenital anomalies to these drugs (70-84). 
 
 
Mycophenolate Mofetil 
 
Mycophenolate is not advised during pregnancy due to the multiple congenital anomalies 
reported with its use (70;72-75;78;80;81;83;84). Multiple case reports and series, including 
the transplant data, support the teratogenicity of Mycophenolate exposure in utero (70;72-
75;78;80;81;83;84). A specific phenotype including microtia, auditory canal atresia, cleft 
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lip and palate, micrognathia, hypertelorism, short fingers and hypoplastic nails has been 
identified (74).  
 
A recent prospective study of the European Network of Teratology Information Services 
investigated 57 pregnancies exposed to mycophenolate in the first trimester (74). In total 
45% of the pregnancies ended in spontaneous abortion (74). Congenital malformations 
were identified in 6 out of 29 live born children; four of these infants had a clinical 
phenotype consistent with mycophenolate embryopathy (74). There was a 26% 
malformation rate after mycophenolate exposure, which means that patients should be 
informed of the need for effective contraception whilst taking the drug (74). 
 
Women are recommended to switch to an alternative drug compatible with pregnancy such 
as azathioprine. A recent study found that in women with quiescent lupus nephritis who 
switched to azathioprine had a low risk of renal flares(85). 
 
 
Methotrexate 
Methotrexate is a folate antagonist, which is also used to induce medical abortions. Data 
from animals and humans exposed to methotrexate in utero have reported congenital 
anomalies, which usually involved the central nervous system, cranial ossification, the 
limbs and the palate and growth restriction (79;82). In view of this it is recommended that 
methotrexate is stopped three months prior to conception(86) .  
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Cyclophosphamide 
Cyclophosphamide is a human tetragon, and effective contraception must be used. 
Cyclophosphamide embryopathy, including anomalies of craniofacial structures, ears and 
limbs, visceral organs, growth restriction and developmental delay during have been 
reported in the literature(79). Recent case reports have confirmed the teratogenicity of 
cyclophosphamide (76;77). 
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Medications and DMARDS considered compatible with pregnancy and lactation 
 
Disease modifying anti-rheumatic drugs that are considered safe in pregnancy and 
breastfeeding are: hydroxychloroquine, azathioprine, sulphaslazine, ciclosporin and 
tacrolimus(79). 
 
  
NSAIDS (Non Steroidal Anti-Inflammatory Drugs) 
Patients who are struggling to conceive are advised to stop taking NSAIDS as there is 
possible increased risk of luteinized unruptured follicle syndrome (87;88).  This condition 
is characterized by clinical signs of ovulation with the absence of follicular rupture and 
ovum release, which is caused by the inhibition of the cyclooxygenase- 2 (COX-2) needed 
during follicular development. 
NSAIDS can be used in pregnancy in short limited courses, care must be taken with their 
use as they can be linked with maternal renal and cardiac failure, hypertension, and fluid 
overload, and oligohydramnios and renal impairment in the fetus if used for long periods 
of time(79;89). However NSAIDS must be stopped at the end of pregnancy, after week 32, 
as they are associated with an increased risk of preterm closure of the patent ductus 
arteriosus in the fetus(79;89;90).  
 
30	  
	  
Aspirin and Heparin    
Pre-eclampsia is increased in SLE patients, compared to the general population, as 
discussed earlier. Low dose aspirin has been demonstrated to reduce the risk of pre-
eclampsia in all pregnant patients considered to be at risk of pre-eclampsia, relative risk of 
0.81, 95% CI 0.75-0.88, there is a modest reduction in preterm delivery, neonatal death and 
IUGR(91).   
In pregnant SLE patients with Antiphospholipid Syndrome (APS), a Cochrane Review 
concluded that combined unfractionated heparin and aspirin, compared to aspirin alone, 
may reduce the risk for pregnancy loss (RR 0.46, 95% CI 0.29 to 0.71)(92).  The 
combination of low-molecular-weight heparin and aspirin compared to aspirin alone, was 
not so effective (RR 0.78, 95% CI: 0.39 to 1.57)(92). More recent meta-analyses have 
demonstrated the benefits of combined treatment with aspirin and heparin during 
pregnancy, but further evidence is needed to confirm that low weight molecular heparin is 
equivalent to unfractionated heparin (93;94).   
 
 
Steroids 
Non fluorinated steroids (prednisolone, methylprednisolone and hydrocortisone) are 
metabolised by placental 11 β-hydroxysteroid dehydrogenase, and less than ten percent is 
found in the fetal circulation(95).  Oral steroids are considered compatible with pregnancy, 
potential side effects for mothers are as for non-pregnant women. Those of relevance to 
pregnancy include increased blood pressure, osteopenia, osteonecrosis and susceptibility to 
infection are of special relevance in pregnancy. The risk of gestational diabetes will be 
increased, as pregnancy induces insulin resistance and glucose intolerance.  
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Fluorinated steroids (dexamethasone and betamethasone) can cross the placenta and are 
recommended in pregnant women to improve surfactant levels before preterm birth(96). 
Fluorinated steroids are also used for myocarditis and hydrops in babies with CHB (40;97). 
 
Hydroxychloroquine 
Hydroxychloroquine has been demonstrated to be safe in pregnancy and lactation, with 
most studies on infants demonstrating normal visual function and neurodevelopmental 
outcome (98-104). There were no statistically significantly increase in congenital 
anomalies in a recent prospective observational study(105). The safety and benefits of 
using hydroxychloroquine therapy in pregnancy was also demonstrated in systemic 
reviews (103;104).  
 
A randomised controlled study found that women with SLE who continued 
hydroxychloroquine throughout pregnancy, had lower disease activity and lower 
prednisolone doses at the end of pregnancy(100). This was corroborated in a further study, 
in which women with SLE who discontinued or had never taken hydroxychloroquine, had 
higher disease activity scores and were on higher doses of prednisolone, compared to those 
who had continued hydroxychloroquine (99).  
 
It is important to note that hydroxychloroquine has a half-life in the blood of 
approximately 50 days, so even if stopped in pregnancy or prior to lactation, it will still be 
present in the maternal blood and breast milk and many more babies have been exposed to 
it than is generally recognised. 
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Azathioprine 
Azathioprine is an antimetabolite immunosuppressant used to treat SLE, IBD 
(inflammatory bowel disease), haematological malignancies and transplant patients. 
Azathioprine has been used in solid organ transplantation for more than 50 years and is 
used frequently for therapy of organ-threatening autoimmune diseases. Previously 
published reports investigating mothers who take azathioprine during pregnancy and 
lactation, found that the concentration of azathioprine’s active metabolite, 6-
mercaptopurine, in breast milk was negligible(106). The fetus is thought to be protected 
from the potential teratogenic effects of the drug as they lack the enzyme 
inosinatopyrophophorylase that is required to convert azathioprine to the active metabolite 
6-MP.  The teratogenic effects of azathioprine have been reported in animal studies, where 
higher doses were administrated (79).   However there was no increase in the rate of 
congenital anomalies in humans in previous studies (79). 
 
Sulphasalazine 
A meta-analysis of women with IBD showed that sulfasalazine is not related to teratogenic 
effects (107). Sulphasalzine inhibits the gastrointestinal and cellular uptake of folate, 
women should be advised to take high-dose folic acid (5 mg/day) from 3 months prior to 
conception until at least the end of the first trimester, in order to reduce the risk of neural 
tube defects.  
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Ciclosporin  
Ciclosporin is considered compatible with pregnancy and breast feeding, greater than 800 
human pregnancies have been published in the literature (108) . However care must be 
taken when using ciclosporin, as an increased rate of hypertension, pre-eclampsia and 
gestational diabetes have been reported with its use (108). Ciclosporin should be 
prescribed at the lowest effective dose with monitoring of blood pressure and renal 
function (79;108). No concerns have been identified with breast feeding(109). 
 
 
Tacrolimus  
Tacrolimus is considered to be compatible with pregnancy and breast feeding, the majority 
of data on tacrolimus use is from the transplant literature (110-113), There have been case 
reports of its successful use in refractory disease in the rheumatology 
population(110;111;114). A recent publication reported that tacrolimus has been 
successfully used in pregnancy both to treat women with stable disease and lupus nephritis 
flares, whilst preventing the commencement and/or escalation of steroids in the majority of 
cases(115). Minimal levels of tacrolimus have been identified in breast milk, and blood 
levels were not found to be higher when breast fed and bottle fed infants were studied 
(116;117).  
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Pre pregnancy counselling 
Women of childbearing age should be advised regarding the importance of good disease 
control before conception, the need for close monitoring during pregnancy, and the risk of 
postpartum disease flare.  
 
It is essential that a full clinical history, including current and past SLE disease 
manifestations and antibody profile is obtained, specifically including antiphospholipid 
antibodies, anti-Ro/SSA or anti-La/SSB. Contraindications to pregnancy should be 
identified, including pulmonary hypertension, active disease and contraindicated drugs 
(118). 
 
As in the general population, all women should be encouraged to stop smoking, to 
reduce/cease their alcohol and take folic acid (0.4  mg/day) 12 weeks before and after 
conception in order to prevent fetal neural tube defects. 
 
Contraindicated drugs should be replaced with drugs compatible with pregnancy, as 
discussed in the medications in pregnancy section. Women taking steroids and those with 
risk factors for diabetes including maternal ethnicity, polycystic ovary syndrome, should 
have a glucose tolerance test around 24–28 weeks’ gestation in order to exclude gestational 
diabetes and avoid further obstetric risk(119). Patients who take steroids, heparin or have 
other risk factors for osteoporosis should take prophylactic calcium and Vitamin D 
supplements(119). 
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Women with anti-Ro/SSA or anti-La/SSB autoantibodies will require regular fetal heart 
monitoring from week 16 by the midwife or obstetric unit (13;120). Thus heart block can 
be identified as early as possible and treatment can be initiated if necessary. As early 
identification and prompt treatment with dexamethasone may dampen down myocarditis or 
cardiac failure, but there is no evidence that it prevents development of CHB (40;41). 
There is no evidence that IV immunoglobulin will prevent the occurrence CHB (42-44).  
Women with antiphospholipid antibodies will require treatment with low dose aspirin, 
combined with low molecular weight heparin in certain circumstances including recurrent 
early miscarriages (<10 weeks of gestation), women with previous fetal death (>10 weeks 
of gestation) and/or preterm delivery (<34 weeks gestation) (93;118;119). 
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Data in the literature on the long-term outcomes of children 
 
This section will review what is known in the general population, lupus and transplant 
groups, on the relevant long-term outcomes. The transplant population has been chosen, as 
many of the mothers will be taking similar drugs throughout pregnancy. In addition renal 
disease itself will predispose mothers to an increased risk of similar confounders including; 
hypertension, IUGR and pre-eclampsia. 
 
 
CHB 
CHB is associated with anti-Ro/SSA or anti-La/SSB autoantibodies, it is estimated to 
occur in 2% of pregnancies, the risk of reoccurrence in a subsequent child is increased to 
20% (33;40;121;122).  There is a 10–20% risk of perinatal death amongst affected children 
and most of surviving children need a permanent pacemaker (123;124). Incomplete forms 
such as first or second-degree heart block, can progress to complete forms during 
childhood(120). 
Retrospective data were reviewed comparing children with complete CHB, born to 
mothers with anti-Ro/SSA antibodies with their unaffected siblings, Impaired 
neurodevelopment was reported in 16% of the children (18/114) during a median follow-
up time of 13 years(125).  Reported problems included speech (9%), motor (8%) and 
learning (8%) impairment, attention deficit (5%) and behavioural impairment (4%)(125). 
Learning impairment was significantly influenced by maternal SLE (p < 0.005), while 
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attention deficit was influenced by both maternal SLE (p < 0.05) and CHB in the child (p < 
0.05)(125). This study indicates that both maternal SLE and CHB may influence 
neurodevelopment in those children (125). 
 
Long term outcomes of children born with CHB, have been reported in 91 infants from 
Finnish tertiary referral centres(124). In total 82% of the cohort were alive at 10 years, 
mortality was associated with congestive dilated cardiomyopathy(124). Cardiac pacing was 
required in 53% of neonates and 40% required pacing after the neonatal period(124). 
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Congenital anomalies 
The EUROCAT (European surveillance of congenital anomalies) data, derived the overall 
prevalence of major congenital anomalies in the general population diagnosed during 
pregnancy, at birth, or in early infancy at 26 per 1000 births in 2010(126).  
 
SLE literature 
There has been a small study on the risk of congenital physical abnormalities in 30 
children born to mothers with lupus in the United States of America (USA) , which 
demonstrated a similar incidence to that of the general population (98). A population 
registry study in Western Australia, linked dispensed prescriptions with a birth defects 
registry for a 3 year period (2002-5), to calculate an OR (odds ratio) when comparing the 
number of birth defects if a minimum of one prescription was dispensed during pregnancy, 
with that of all offspring not exposed to that medication(72). This study identified an 
increased risk of congenital anomalies, following pregnancies where at least one 
prescription was dispensed for hydroxychloroquine (72). This study did not take account of 
several confounders including: maternal age, diagnosis and other medications (72). In 
addition the results are not statistically significant as the 95% confidence interval for the 
OR crosses one (72).  
 
An abstract from a recent Canadian, case control study, analysing medical databases of 507 
women with SLE who had 721 children and 5862 matched healthy controls who had 8561 
children, reported slightly more major congenital anomalies, [13.6% (95% CI 11.3, 16.3) 
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compared with 10.4% (95% CI 9.7, 11.1)], in controls(127). The congenital anomalies 
associated with certain drugs have been discussed in the medication in pregnancy section. 
 
Transplant literature 
A large study, which assessed the outcome of 362 children, born to mothers after kidney 
transplant, found a birth defect rate of 5% (110). No predominant pattern of malformations 
was identified in this study(110). It has been reported by the NTPR (National 
Transplantation Pregnancy Register), that although the rate of congenital anomalies in the 
transplant population is comparable with that of the general United States population, there 
is a substantially increased anomaly rate of 23%, in those pregnancies where there has 
been in-utero mycophenolate mofetil exposure (128). The observed pattern of 
malformation associated with Mycophenolate in both animal models and human data have 
resulted in the recommendation in the renal literature that mycophenolate should be 
stopped and an alternative agent should be started before conception (74). 
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Immune function and risk of infection 
 
Prematurity and low birth weight in the general population are associated with an increased 
risk of infections, the risks have been estimated to be three to tenfold compared to full term 
normal birth weight infants(68).  It has also been demonstrated that the risk for adverse 
fetal outcomes including; mechanical ventilation, new born sepsis, hypoglycaemia, 
admission to the neonatal intensive care, and hospitalization for 5 days or more; are 
significantly reduced for every week that elective caesareans are performed after 37 weeks 
gestation(129). Low birth weight is associated with a significant increase in adolescent 
(aged 12-20) hospital admissions for respiratory complaints, including infections(130). The 
relationship was stronger in adolescents who had a very low birth weight (<1.5kg) 
compared to those with a moderately-low-birth weight (1.5-2.499kg)(130). This 
relationship was maintained when adults with a history of very low birth weight or 
moderately low birth weight were compared to age matched controls (131). Studies have 
also demonstrated a relationship between low birth weight and reduced lung function in 
adult life (132;133).   
 
The long term outcomes of children who are breast fed by women with IBD was compared 
in those who did or did not take azathioprine (134). The mean age of children was 3.3 
years in the azathioprine exposed group and 4.7 years in the control group, there was no 
statistical difference in rates of hospitalisation for infection between the two groups (134). 
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SLE literature 
There have been several small studies investigating both the humoral and cellular 
components of immunity in children born to mothers with connective tissue diseases 
exposed to immunosuppression in utero (102;135-137).  
 
A number of small studies have demonstrated that children born to mothers with 
connective tissue disease, exposed to immunosuppression in utero have normal levels of 
serum IgG subclasses and lymphocyte subpopulations (102;135). 
 
 
The immune response to the C.Tetani toxoid was assessed, by evaluating the titre of 
circulating antibodies, in twenty-two babies born to mothers with a connective tissue 
disease taking hydroxychloroquine or dexamethasone during pregnancy (137).  There was 
no clear relationship between specific drug exposure and antibody response in the five 
children who did not achieve a protective titre of anti C. Tetani (137). In contrast, another 
study, which assessed the response to hepatitis B vaccination, in nine children, found that 
all the children had a satisfactory response to hepatitis B vaccination, in addition to normal 
Lymphocyte subpopulations, serum immunoglobulin levels, and IgG subclasses serum 
levels (136).  
 
 
An abstract from a recent Canadian, case control study, analysing medical databases of 507 
women with SLE who had 721 children, and 5862 matched healthy controls who had 8561 
children, reported slightly more serious infections, 31.5% (95% CI 28.2, 35.0) compared 
with 26.0% (95% CI 25.1, 26.9) of controls(127). Serious infections in this study were 
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identified as greater than one hospital admission with a primary diagnosis of infection 
These serious infections were also reported at a younger age in the children born to 
mothers with SLE, 1.8 (95% CI 1.6, 2.0) years of age for children born to women with 
SLE and 2.1 (95% CI 2.0, 2.2) in the control group(127). The increased rate of serious 
infection in children born to mothers with SLE, remained after multivariate analysis, 
(adjusted HR 1.76, 95% CI 1.21, 2.56)(127). 
 
What is known about infection risk  in children  exposed to immunosuppression from 
the Transplant data 
 
There is little long term data of child outcomes in the renal literature, some very small 
studies, which reviewed six patients in the renal literature concerning children exposed to 
immunosuppression, the studies found that B and T cells were low at birth and when 
repeated in one of the studies had normalised within a few months (138-140).  These 
infants did not develop opportunistic or chronic infections, and had a normal growth during 
their first year of life. However, the authors suggested that conventional vaccinations 
should be delayed in these infants(141). 
 
Larger studies of renal transplant registry data, have used telephone interviews and/or 
questionnaires, to collect long term information on children born to renal transplant 
recipients, and have not found any reported immune dysfunction in the children (110;128). 
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Developmental problems  
 
Several studies have been carried out in the general population that have identified possible 
associations with developmental problems as outlined below. Developmental problems 
was used as a collective term to describe developmental delay, Attention Deficit disorder, 
special needs and special schooling, identified by a relevant health care professional in this 
study.  
Very low birth weight (<1.5kg) and very preterm (27-33 week) infants, have an increased 
risk of long term educational and behavioural difficulties (142-146) 
Delays in several neurodevelopmental domains, including attention and social interaction 
were reported to be significantly reduced in small for gestational age term infants with 
normal placental function when compared to the general population (147) 
There are a number of factors that can have an adverse effect on perinatal and early 
childhood brain development in the general population.  An increase in the risk of ADHD  
(Attention Deficit Hyperactivity Disorder) or attention deficit disorder without 
hyperactivity is associated with maternal smoking, alcohol consumption, very low birth 
weight and fetal hypoxia(148). There are papers in the literature on Attention Deficit 
Hyperactivity Disorder and autism and autoimmunity that are described in the discussion. 
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SLE literature 
1.2.1.1	  The	  role	  of	  autoantibodies	  and	  developmental	  problems	  
 
Maternal autoantibodies, which are known to cross the placenta, have been implicated as a 
contributor to developmental problems. The fetal blood-brain barrier is not fully formed, so 
the developing brain is exposed to maternal autoantibodies. 
 
 
a. Anti-phospholipid Antibodies 
 
 
A previous case control study, found increased evidence of developmental problems, 
particularly in male children (149). A previous study which studied forty-seven offspring 
of SLE patients, found that maternal SLE does not impair intelligence levels, but may 
increase the occurrence of learning difficulties, the three children with impaired learning 
difficulty tests were all born to mothers with anti-phospholipid antibodies (150). 
 
Recent data from the European neonatal registry of babies born to mothers with 
antiphospholipid syndrome, which observed forty-two children up to twenty four months, 
identified four children with developmental problems(52). The identified developmental 
problems were: one case of autism, two cases of learning disabilities and one case of 
psychomotor delay associated with axial hypertonia(52).   All four children were born at 
term, to mothers with primary purely obstetric anti-phospholipid syndrome, treated with 
both aspirin and heparin during pregnancy(52). There is a passive acquirement of maternal 
antiphospholipid antibodies in a sub-group of 30 children compared to age matched 
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controls, when fetal blood was examined, there was an absence of clinically evident 
thrombotic events (52). 
 
 
b. Anti-Ro/SSA and/or anti-La/SSB antibodies 
 
Anti-Ro and/or anti-La antibodies have known effects on the fetal heart, skin, blood and 
liver. It has been postulated that since the blood-brain barrier is not fully formed in utero, 
that antibodies may be able to cause neurological damage as part of the neonatal lupus 
syndrome (151;152).  
 
A large multicentre cohort study recruited, hundred and four anti-Ro exposed offspring 
with a mean age of 14.5 years (range 5-39) and twenty-two friend control children, mean 
age 11.2, good matching was demonstrated for gender, ethnicity, race and socioeconomic 
status(151). In total forty-two (40%) of the 104 anti-Ro exposed children were reported by 
their parent to have a neuro-psychiatric disorder, compared with 6 (27%) of the friend 
controls (p = 0.34).  Neuro-psychiatric disorders included depression, anxiety, 
developmental delays, learning, hearing, and speech problems, which individually were not 
significantly different between groups (151).  
 
 
A case control study comparing 58 children born to mothers with SLE with58 healthy 
controls, found that sons of women with SLE were more likely to have a learning difficulty 
than the daughters of women with SLE and children of either sex in the control 
group(153), Children in both groups were age, sex, and socially class matched 
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children(153) The significant risk factors associated with learning difficulties were flare of 
maternal SLE in pregnancy and the presence of anti-Ro/SSA and/or anti-La/SSB 
antibodies(153). Children were assessed using a standardised intelligence test (Wechsler 
Intelligence Scale for Children-III), standardised tests for reading, arithmetic, and writing 
achievement.(153).   
 
A retrospective study, which tested 49 pairs of SLE offspring and matched controls, 
revealed impairment in the SLE offspring group in two of the nine domains: learning and 
memory and behaviour(154). The pairs were matched for ethnicity, age, sex and 
socioeconomic status(154). However it is difficult to draw conclusions from such small 
numbers(154). 
A study that evaluated 47 children (23 male and 24 female) born to women with SLE, 
included age appropriate testing (150). In total 3 children were identified to have learning 
difficulties, all three children’s mothers were antiphospholipid antibodies (aPL) were 
positive, other maternal autoantibodies or drugs administered during pregnancy were not 
associated with learning difficulties(150). 
 
 There have been small studies which observed and tested the offspring of SLE patients for 
neurocognitive/psychiatric impairment, which suggested that there may be an increased 
risk of neuropsychological and learning difficulties (150;154).  
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1.2.1.2 Drugs and developmental problems 
a. Dexamethasone 
 
A study assessed neuropsychological development in a total of sixteen children; eleven 
children with CHB born to mothers with anti-Ro/SSA antibodies, who were exposed to 
high dose dexamethasone in utero, two children not exposed to in-utero dexamethasone 
and three healthy siblings, all of anti-Ro/SSA-positive women, were evaluated health 
controls (155). The mean age of the children was five (range 2–12) years, eleven were 
preschool age mean age 3.01, (range 14–65 months) and five of school age (7–11 years) 
(155). Age appropriate tools were used to assess IQ(155). The mean total dose of 
dexamethasone in exposed children was 186.6 mg (155). Children had normal IQ (mean 
IQ 105.1, standard deviation (SD) 9.5) (155). Only one child had a learning disability, of 
borderline clinical significance, but this child had never been exposed to dexamethasone 
(155). Data in the literature have suggested an increased risk of development problems in 
the offspring of non SLE women exposed to fluorinated steroids 
(dexamethasone/betamethasone) during pregnancy (79;156). 
 
 
 
What is known about the risk of developmental delay from the Transplant Data? 
 
Data available from the NTPR (National Transplantation Pregnancy Register) based in the 
United States identified 304 female kidney recipients on ciclosporin-based 
immunosuppression, with 456 pregnancies delivered between March 1983 and November 
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1999. Initially, 133 female recipients were contacted for information on their 175 
children(128). In this group, 71 of the children were older than 5 years, and 8 (11%) of 
these were diagnosed with ADHD (110;128). Two years subsequent to this initial survey, 
114 of 133 recipients were again contacted, and detailed information was gathered on 147 
children(110). At follow-up, the mean age of the children was 6.5 ± 2.8 years(110). The 
rate of ADHD was similar to that found in the general population(110). 
 
Summary 
 
 
 
There is a gap in the literature when counselling women with SLE, regarding the risks of 
her child needing hospital attention or special schooling during childhood. In addition there 
is a paucity of data regarding how the mother’s disease type or activity, antibody profile 
and drug use in pregnancy, may affect the child’s outcome. 
 
Providing women with SLE with up to date and evidence-based information on the 
potential risks of pregnancy for both themselves and their offspring will help to address 
both patient’s expectations and knowledge when deciding to plan a family. There are few 
published studies in the literature on the long term effects on children born to mothers with 
SLE. Further research into this area will provide evidence for pre-pregnancy counselling, 
an essential component of holistic care, enabling mothers to make an informed decision. 
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Studies in the literature have looked at certain outcomes for children born to mothers with 
SLE including, neonatal lupus, CHB, physical anomalies and neuropsychological 
development, but there is nothing in the literature that considers all these factors together. 
This study aimed to assess a large cohort of UK children born to mothers with SLE seen at 
BILAG (British Isles Lupus Assessment Group) centres in the UK. 
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Aims and Objectives 
 
The primary aim is to determine the frequency of adverse events, which occur in the 
children born to mothers with SLE, at a national level. These data from a large national 
cohort will also help us to identify and understand the predictors for adverse outcomes in 
children born to mothers with lupus.  
 
The key questions that will be addressed are: 
 
 
1. Does exposure specifically to hydroxychloroquine during pregnancy and/or breast 
feeding alter the risk of: 
      1. Maternal Complications 
Pre-eclampsia 
IUGR 
2. Neonatal Outcomes 
Congenital anomalies  
Complete heart block 
3. Long term Outcomes of child 
Hospital management of infection 
Developmental problems 
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2. Does exposure to azathioprine specifically during pregnancy and/or breast feeding 
alter the risk of: 
1. Maternal Complications 
Pre-eclampsia 
IUGR 
2. Neonatal Outcomes 
Congenital anomalies  
3. Long term Outcomes of Child 
Hospital management for infection 
Developmental problems 
 
3. Are there any non-drug risks and/or protective factors related to lupus disease in 
mother (particularly autoantibodies), pregnancy complications or fetal drug 
exposures when looking at infection requiring hospital management?  
 
  
4. Are there any non-drug risk and/or protective factors when analysing congenital 
anomalies? 
 
5. Are there any non-drug risk and/or protective factors when analysing child 
development?   
i. Developmental delay   
i. Delay in achieving milestones  
ii. Special Needs and/or Special schooling   
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i. Defined as a child that was deemed to require specialist schooling 
by an appropriate professional 
iii. Attention Deficit Disorder 
i. Diagnosed by an appropriate health professional and sufficient to 
require a defined intervention 
 
Following initial univariate analysis, multivariate analyses will be carried out to determine 
if adjusted maternal risk factors are associated with adverse outcomes. 
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Methods 
2.1 Data Collection 
The study was approved and conducted in compliance with regulations of relevant ethics 
committees (South Birmingham National Research Ethics Service and hospital research 
and development departments) and all participants provided written consent in accordance 
with the Declaration of Helsinki. 
 
Retrospective data were collected using an approved questionnaire designed to address the 
questions, developed to address aims and objectives. See appendix for further details. The 
inclusion criteria were: women who had a pregnancy after fulfilling a minimum of four 
ACR criteria for SLE, had a child below the age of seventeen and who regularly attended a 
rheumatology outpatient department. Any patients that did not fulfil the inclusion criteria 
were excluded. If a child was over the age of twelve at recruitment, then assent was taken 
via the mother, as approved by the ethic committee.  
 
 There were a total of 10 centres, Birmingham (Birmingham Women’s Hospital, Queen 
Elizabeth/University Hospital, and City Hospital), London (St Thomas’s and University 
College London), Bath, Manchester, Blackburn, Sheffield and Southampton. The data 
collected were from a non-selected sample. All eligible patients should have been 
approached to take part and we are unaware of any bias in recruitment. Data about patients 
that refused were not routinely collected.  Data were excluded if the mothers had not 
developed a minimum of four ACR criteria, by the time the child was born, and if a child 
was over the age of seventeen.  
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In total data were collected for 287 children, born to 200 women after the fulfilment of a 
minimum of four ACR criteria for SLE, making this one of the largest studies to date.  
 
The data were collected using the standardised questionnaire by a physician or research co-
ordinator (nurse or research assistant) at the specialist centre. The first part of the 
questionnaire collected data on number and dates of pregnancies, drug exposure, smoking 
and alcohol intake during pregnancy, and the outcome in terms of miscarriages, stillbirths, 
live births, preterm delivery, birth weight and gestational age and data on maternal disease 
including antibodies, ACR criteria and renal biopsy results.  
 
A second part of the questionnaire was completed by the mother to collect data on 
outcomes of children up to the age of 17 including; neonatal lupus syndrome (including 
CHB), any other congenital malformations, any outpatient visits or admissions to hospital, 
including the diagnosis of developmental delay and the need for special schooling, 
recurrent or serious infections and any chronic illnesses. Information was also collected 
about immunisations and prescribed drugs (other than antibiotics, cough mixtures and 
calpol) that the children have received, but the data were not analysed. 
The relevant general practitioners or hospital doctors were contacted and notes reviewed as 
necessary to confirm details. 
Children were defined as having an infection requiring hospital assessment if they had an 
in or outpatient visit due to infection, to account for different admission policies in 
different units. Children were defined as having a congenital anomaly based on the 
EUROCAT definitions(157) 
55	  
	  
 
2.2 Data Analysis 
 
The data were analysed to produce mean and SD for continuous variables, median and 
range for non-continuous data. Categorical data were presented as frequencies and 
percentages. Preliminary analysis of categorical variables and normally distributed 
continuous variables utilised chi squared, or fisher’s exact test for low frequency 
characteristics. Continuous variables that are non-parametric were analysed using Mann-
Whitney U test.  Multivariable logistic regression was used to adjust for variables 
considered to be clinically relevant (potential confounders) based on previous literature 
regardless of statistical significance on univariate analysis.  
This enabled the calculation of ORs, p values and 95% CIs to assess the association 
between maternal/fetal factors and the outcomes of interest. All statistical analyses were 
performed using SPSS version 22. Detailed data analysis plan for each long term outcome 
studied are included in the appendix. 
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 Results  
Overall data Summary 
In total data were analysed for 199 women, and 285 live born children. Overall the median 
age of mothers at delivery was 32 as shown in table 4. The overall ethnic mix was; 67% 
Caucasian, 16% South Asian, 11% Afro-Caribbean, 1% Chinese, 1% Hispanic and 4% 
other (Table 15). The ethnic mix of patients in this study is representative of a typical UK 
lupus cohort. 
 
The median age of children at assessment in this study was 3 years, with a range of 0.1-
17.3 years, as shown in Table 8. The age distribution of children at entry into the study is 
summarised in Table 19. The median gestational age at delivery was 38 weeks, with a 
range of 25-42 weeks and median birth weight of 2.94kg (Table 8). There was no 
statistically significant difference in the number of male or female children recruited, as 
shown in Table 8. The data are presented for the whole cohort and then subdivided by 
exposure to hydroxychloroquine, and then exposure to azathioprine.  
 
Additional maternal items that were not analysed by drug exposure are in the appendix; 
supplementary tables section, (Tables 15-21). The following additional maternal 
demographical data are available (Table 15) in the appendix: maternal ethnicity, maternal 
years in education, pregnancy number, smoking (current, ex-smoker or nonsmoker) and 
alcohol intake during pregnancy. Additional tables available in the appendix are: maternal 
drugs in pregnancy (Table 16), maternal drug combinations (Table 17) and maternal 
antibody status (Table 18). 
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Child demographic data on age at entry and mode of delivery (Table 19) are included in 
the appendix. Additional data on infection (Table 20) and developmental delay by age 
(Table 21) are also in the appendix.  
 
 
Maternal Demographics 
The maternal demographics are summarised in table 4. The median age at delivery was 32 
in all women, regardless of drug exposure Table 4. In total 34% (92/275) of the population 
were Caucasian and 66% (183/275) were all other ethnicities/racial groups combined. 
There were significantly more Caucasians, 72%, (107/148) in the hydroxychloroquine 
group (versus 60% (76/127) in the non hydroxychloroquine group (p=0.029). There was no 
ethnic differences identified comparing azathioprine exposed (Caucasian, 63%, 52/83) and 
unexposed (Caucasian 68%, 131/192), p=0.368. The median disease duration was 6 years 
in the whole cohort, Table 4. The disease duration range was very wide (0-27 years), 
reflecting the small number of women who had lupus diagnosed around puberty, and had 
children in their late thirties, Table 4. Disease duration prior to pregnancy was significantly 
longer in those who took azathioprine during pregnancy and/or breast-feeding (7 versus 6 
years, p=0.0078) Table 4.  No significant difference was identified in the disease duration 
between hydroxychloroquine and no hydroxychloroquine groups.  
 
 
Maternal Drugs 
Maternal medications ever taken throughout conception, pregnancy and breast feeding (if 
applicable) are summarised in tables 7, 16 and 17. When the data were reviewed, it was 
identified that the vast majority of children were exposed during both pregnancy and 
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breastfeeding, so there was an insufficient difference to justify a separate analysis for each 
of these.  
The majority of women (71%) took aspirin and over half took prednisolone and 
hydroxychloroquine (53%) during pregnancy and/or breast feeding, as shown inTable	  16	  -­‐	  
Maternal	  Medication. There was a statistically significant increase in steroid use during 
pregnancy and/or breastfeeding, in the azathioprine group (87%) compared to the no 
azathioprine group (47%) (p<0.0001) (Table 7). The increased use of steroids in the 
hydroxychloroquine group (65% Vs 53%, in the no hydroxychloroquine group, p=0.052) 
Table	  7 was not significant. There was a significantly increased use of aspirin in the 
azathioprine group (81%) versus the no azathioprine group (66%), p=0.013, which may 
reflect that these patients had more severe disease (Table	  7). 
 
 
Maternal Antibodies 
The presence of maternal anti-double stranded DNA antibodies and lupus anticoagulant 
and/or anticardiolipin antibodies was statistically higher in the azathioprine exposed group 
(table 6). However the presence of the antibodies individually or in a diagnosis of maternal 
anti-phospholipid syndrome was not found to be significantly different between any of the 
treatment groups. Anti-Ro and/or anti-La antibodies were present in 43% of patients 
overall and there were no statistically significant differences associated with different drug 
exposures table 6. 
 
 
Maternal disease Characteristics 
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In this study we used a history of renal biopsy as a surrogate marker for renal disease. This 
was felt to be something that mothers would be able to accurately recall. In the 243 
pregnancies for which this data was obtained, a renal biopsy had been performed in 27% 
(65 pregnancies)table 4. 
 
There were significantly more women in the azathioprine group who had had a previous 
renal biopsy, which is likely to signify more severe disease in this group. In total 16% 
(44/275) of the cohort had a history of hypertension prior to pregnancy, and the 
proportions were significantly increased in the group who did not have 
hydroxychloroquine during pregnancy and/or breast feeding and the group who took 
azathioprine during pregnancy and/or breast feeding (table 4). 
 
Pregnancy Complications 
There were no statistically significant differences in the rate of hypertension during 
pregnancy, pre-eclampsia or IUGR between the groups, and these were reported in the 
overall cohort at 17%, 10% and 12% respectively Table 5. This was despite the statistically 
significant increase in maternal steroid and renal disease in the azathioprine group 
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Table	  4	  -­‐	  Maternal	  Characteristic's  
	  
HCQ= Hydroxychloroquine, AZA = Azathioprine 
 
All p values were calculated using Pearson’s Chi2, except where indicated by *symbol.  
The *p values were calculated using a Mann–Whitney U test for continuous variable 
	  
Median, range, 
IQR 
Or n (%) 
All 
n=285 
children 
HCQ 
n=150 
Children 
NO HCQ 
n=135 
Children 
p Value AZA 
n=87 
No AZA 
n=198 
p value 
 
Age at 
delivery 
 
32  
(19-44) 
7 
 
32 
 (19-44) 
7 
 
32 
 (19-42) 
7 
0.279* 
 
32.5, 
 (22-42) 
 6 
 
32.0,  
(19-44)  
7 
0.508* 
Disease 
Duration yrs.  
 
6  
(0-27)  
7 
6  
(0-21) 
7 
7  
(0-27)  
8 
 0.107* 
7.0   
(1-21)  
7 
6.0 
(0-27) 
 8 
 0.0078* 
Previous 
Renal biopsy 65/241 (27) 32/132 (24) 32/109 (29) 0.371 37/66(56) 27/175(15) <0.0001 
Hypertension 
prior to 
pregnancy 
 
44/275(16) 16/144(11) 28/131(21) 0.020 31/82(38) 13/193(7) <0.0001 
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Table	  5	  Pregnancy	  complications	  
	  
	  
	  
HCQ=	  Hydroxychloroquine,	  AZA	  =	  Azathioprine	  
All	  p	  values	  were	  calculated	  using	  Pearson’s	  Chi2	  
	  
Median, range, 
IQR 
Or n (%) 
All 
n=285 
children 
HCQ 
n=150 
Children 
NO HCQ 
n=135 
Children 
p Value AZA 
n=87 
No AZA 
n=198 
p value 
 
Hypertension 
during 
pregnancy 
48/278(17) 27/149 (18) 21/129(21) 0.685 12/84(14) 36/194(19) 0.387 
Pre-eclampsia 28/268 (10) 15/143(11) 13/125(10) 0.981 11/82(13) 17/186(9) 0.831 
IUGR 
 31/268 (12) 16/141(11) 15/127(12) 0.906 10/82(12) 21/186(11) 0.376 
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Table	  6	  -­‐	  Maternal	  antibodies	  
HCQ=	  Hydroxychloroquine	  
AZA	  =	  Azathioprine	  
	  
All	  p	  values	  were	  calculated	  using	  Pearson’s	  Chi2,	  except	  where	  indicated	  by	  *symbol.	  	  
The	  *p	  values	  were	  calculated	  using	  a	  Mann–Whitney	  U	  test	  for	  continuous	  variable	  
 
N	  (%) All 
n=285	  
children 
HCQ 
n=150	  
Children 
NO HCQ 
n=135	  
Children 
p	  Value AZA 
n=87 
No AZA 
n=198 
p 
value 
 
Anti-double 
stranded DNA 
ever present 177/268 (66) 91/137(66) 86/131(66) 0.894 58/80(73) 
 
119/198(60) 
  
0.002 
Ro ± La 
antibodies 112/263 (43) 55/141(39) 57/122 (47) 0.207 37/78(47) 75/185 (41) 0.302 
Lupus 
anticoagulant 
and/or 
Anticardiolipin 
IgG and/or IgM 
122/250 (49) 68/131(52) 54/119 (45) 0.302 42/72 (58) 80/178(45) 0.055 
Lupus 
anticoagulant 93/259 (36) 53/137 (39) 40/122(33)  0.323 30/74 (41) 63/185(34) 0.326 
Anticardiolipin 
IgG and/or IgM 
 
67/251(27)  
(23) 
34/132 (23) 33/119 (28) 0.523 25/73(34) 42/178(24) 0.083 
Diagnosis 
Antiphospholipid 
Syndrome 30/254(12) 15/134 (11) 15/120 (13) 0.747 7/77(9) 23/177(13) 0.376 
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Table	  7	  -­‐	  Maternal	  drug	  treatment	  
	  
 
	  
	  
	  
HCQ= Hydroxychloroquine 
AZA = Azathioprine 
 
All p values were calculated using Pearson’s Chi2, except where indicated by *symbol.  
The *p values were calculated using a Mann–Whitney U test for continuous variable 
	  
	  
	  
	  
	  
	  
	  
N	  (%) 
All 
n=285	  
children 
HCQ 
n=150	  
Children 
NO HCQ 
n=135	  
Children 
p	  Value AZA 
n=87 
No AZA 
n=198 
p value 
 
Steroids 169/285(59) 97/150 (65) 72/135(53) 
 
0.052 
borderline 
76/87 (87) 93/198(47) <0.0001 
 HCQ 
 150/285 (53) n/a n/a n/a 
44/87 
(51) 
106/198 
(54) 0.740 
Azathioprine 87/285 (31) 44/150 (29) 43/135 (32) 0.740 n/a n/a n/a 
Aspirin 200/282(71) 112/150 (75) 88/150(59) 0.140 69/85(81) 131/197(66) 0.013 
Heparin 69/281(25)  42/149 (28) 27/132 (20) 0.133 27/85 (32) 42/196(21) 0.064 
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Neonatal/Long term child Outcomes (Table	  8) 
 
Although the median gestational age at delivery was 38 in all groups (table 8), there was a 
statistically significant difference between the azathioprine and no azathioprine group, due 
to the different distribution of ages between the different groups. 
 
The median birth weight was significantly reduced in the babies who were exposed to 
azathioprine in utero, compared to the unexposed groups, there was no difference 
associated with HCQ exposure. There were no statistically significant differences in child 
gender between the groups. 
 
The presence of neonatal rash, complete heart block or congenital anomaly using the 
EUROCAT definitions were each reported in 2% of the children in this study. The two 
cardiac congenital anomalies reported were AVSD (Atrioventricular Septal Defect) (n=1) 
and a double aortic arch (n=1). The four other congenital anomalies were Hirschsprung’s 
(n=1), Hypomelanosis of ito (n=1), syndactyly (n=1) and spina bifida (n=1). 
 
Children were significantly younger in the hydroxychloroquine versus non 
hydroxychloroquine exposed group. This is likely to reflect a change in practice, which has 
resulted in more women receiving hydroxychloroquine during pregnancy and/or 
breastfeeding in recent years, due to increasingly reassuring data in the literature. 
 
There was a statistically increased risk of infections requiring hospital management, in 
children exposed to azathioprine during pregnancy and/or breast feeding (37% compared 
with 20%, p= 0.002) table 8. Overall there were a very low number of developmental 
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problems individually or combined in our cohort, and there was no statistically significant 
difference in those children who were exposed or unexposed to hydroxychloroquine or 
azathioprine during pregnancy and/or lactation (if applicable), as shown inTable 8.
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Table 8 - Neonatal and long term outcomes 
 
All p values were calculated using Pearson’s Chi2, except where indicated by *symbol.  
The *p values were calculated using a Mann–Whitney U test for continuous variable 
**Defined using EUROCAT definitions 
Neonatal 
Outcomes 
N(%) or median, 
range, IQR 
All Women 
n=285 
HCQ 
n=150 
No HCQ 
n=135 
P Value AZA 
n=87 
No AZA 
n=198 
p value 
Gestational age at 
delivery 
38, 
25-42 
2                                                       
38,  
25-42 
2 
 
38,  
 25-41 
3
 
0.378* 
 
38,  
28-42,  
3 
38,  
25-42, 
 3 
 
<0.0001* 
Birth weight 2.94 
0.59-4.70 
0.82 
2.89 
0.59-4.35 
0.835  
3.0 
0.65-4.64 
0.873 
0.987* 2.66,  
0.59-4.40 
0.957 
3.0,  
0.65-4.64 
0.820 
0.022* 
Child Gender 
Male 
Female 
 
128/285(44.9) 
157/285 (55.1) 
 
72/150(48) 
78/150(52) 
 
56/135(41) 
79/135(59) 
 
0.269 
 
36/87 (41) 
51/87(59) 
 
 
92/198(46) 
106/198(54) 
 
 
0.427 
**EUROCAT 
Congenital 
anomalies 
6/285 (2.1) 4/150 (2.6) 2/1345(1.5)   0.468 2/87 (2) 4/198 (2) 0.880 
Neonatal lupus 
rash 
6/285 (2) 4/150(2.6) 2/135 (1.5) 0.486 2/87(2) 4/198 (2) 0.880 
CHB 7/285 (2) 4/150 (2.6) 3/135 (2.2) 0.809 2/87(2) 5/198 (2.5) 0.909 
Age of child at 
entry into study 
 
3.00, 
0.1-17.3 
5.4 
 
 
2.29,  
0.07-17.09 
4.23 
 
 
3.93,  
0.13-17.03, 
5.82 
 
 
<0.0001* 
 
 
3.09 
 0.07-17. 
5.87 
 
 
2.88, 
 0.08-16.20, 
 5.02 
 
 
0.709* 
All infections 
requiring hospital 
management 
69/274(25) 
 
35/143(24) 34/131 (26) 0.778 32/86(37) 
 
37/188(20) 0.002 
Developmental 
delay or Attention 
deficit disorder or 
special schooling 
or special needs 
17/284 (6) 
 
6/149 (4) 11/135(8) 0.144 6/87(7) 11/197(6) 0.667 
Developmental 
delay  
14/285 (4.9) 6/150(4) 8/135 (6) 0.485 5/87 (6) 
  
9/198(5) 
  
0.733 
Attention Deficit 
Disorder 
7/285 (2.5) 1/150(0.67) 6/135 (4.44) 0.078 3/87 (3.4) 4/198 (2%) 0.623 
Special Schooling 3/285 (1.1) 0/135 (0) 3/135 (2.2) 0.119 0 3/198 (2) 0.410 
Special Needs 6/285 (2.1) 1/150 (0.7) 5/135 (3.7) 0.132 2/87 (2) 4/198 (2) 0.794 
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Long term outcome Analyses 
Further analyses were undertaken to address the three main long term outcomes of interest; 
congenital anomalies (including CHB), infection and developmental delays. 
Congenital anomalies 
Univariate analysis did not demonstrate any significant associations with congenital 
anomalies, using the 95% confidence interval and two tailed p value for increased 
accuracy. 
 
Table 9 - Congenital anomalies univariate analysis 
Suspected risk factors 
for congenital 
anomalies 
P 
value 
OR 95% 
CI 
min  
95% CI 
max 
Maternal Risk Factors/Characteristics 
Maternal Ethnicity 
(Caucasian Vs all 
others) 
0.995 1.006 0.181 5.594 
Maternal Disease characteristics 
Previous Renal biopsy 0.115 4.303 0.702 26.368 
Anti-phospholipid 
syndrome 0.711 1.510 0.170 13.384 
Maternal Antibodies 
Anti-dsDNA ever 0.974 1.029 0.185 5.726 
Anticardiolipin ±Lupus 
anticoagulant 0.953 1.050 0.208 5.307 
Maternal medications ever taken during pregnancy 
Steroids 0.212 0.335 0.06 1.862 
Hydroxychloroquine 0.493 1.822 0.328 10.109 
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Azathioprine  0.880 1.141 0.205 6.350 
Aspirin 0.269 0.401 0.079 2.029 
Heparin 0.653 0.609 0.070 5.303 
Obstetric/Perinatal 
Hypertension during 
pregnancy 0.308 2.457 0.437 13.811 
Pre-eclampsia 0.089 4.538 0.793 25.987 
IUGR 0.117 4.017 0.705 22.904 
Pregnancy duration 0.507 1.133   0.783 1.640 
Birth weight 0.884 1.092 0.336 3.547 
Log of child age at 
entry 0.894 0.960 0.526 1.751 
 
 
 
 
Congenital	  anomalies	  multivariate	  analysis	  
 
 
An initial larger model, investigated the following variables: birth weight, log of child age 
at entry, maternal drugs (azathioprine, steroids, hydroxychloroquine, aspirin and heparin), 
maternal ethnicity, IUGR, anticardiolipin +/- lupus anticoagulant, pre-eclampsia, 
hypertension prior pregnancy, anti-double stranded DNA, hypertension during pregnancy, 
antiphospholipid syndrome and previous renal biopsy. The only significant risk factors 
identified at the final stage of the analysis (step 14) were previous renal biopsy (OR 11.4, 
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p=0.025, 95% CI 1.35-96.5) and pre-eclampsia (OR =20.895, p=0.017, 95%CI 1.71-256). 
It is of note that although the p values were significant, the 95%CI were very wide.  
 A multivariate analysis using stepwise logistic regression, used the following variables: 
pregnancy duration, birth weight, maternal drugs (azathioprine, steroids, aspirin or heparin 
ever), IUGR, anti-double stranded DNA ever, maternal ethnicity (Caucasian versus all) and 
previous renal biopsy.  The final step (eight) of the analysis is shown below. The models p 
value is 0.49, which is the limit of significance, which is likely due to the low event 
frequency (6 using EUROCAT definitions). The only statistically significant variable was 
IUGR, but the confidence interval is very wide, this link is likely to be due to a baby with a 
congenital anomaly not growing as well in utero. Reassuringly when counselling lupus 
patients these results did not identify any SLE specific risk factors.  
 
Table 10 - Congenital anomalies multivariate analysis 
Suspected 
risk factor 
P value OR 95% CI 
min  
95% CI 
max 
Pregnancy 
duration 
0.144 1.450 0.880 2.386 
IUGR 0.020 15.024 1.525 148.002 
Previous 
renal biopsy 
0.077 5.697 0.827 39.221 
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CHB  
The univariate analysis assessing possible associations with CHB and/or neonatal lupus are 
outlined in Table 8. The only positive association was the presence of maternal anti-Ro 
and/or La antibodies, as expected. 
A logistic regression stepwise analysis model was used to analyse the effects of 
hydroxychloroquine, steroids, azathioprine, anti-Ro, anti-La and anti-Ro and/or anti-La 
antibodies.  Anti-La antibodies had the strongest relationship with CHB, as this was the 
last remaining factor. Steroids were weakly protective against CHB, but this was far from 
significant. 
 
Table 11 - CHB univariate analysis 
 
Suspected risk factors for 
CHB 
P 
value 
OR 95%CI 
min  
95%  CI 
max 
Maternal Risk Factors/Characteristics 
Maternal Ethnicity 
(Caucasian Vs all others) 0.395 2.556 0.294 22.206 
Maternal Disease characteristics 
Previous Renal biopsy 0.705 1.395 0.249 7.807 
Maternal Antibodies 
Anti-Ro 0.042 9.118 1.082 76.854 
Anti-La 0.006 10.250 1.932 54.379 
Anti-Ro and/or La 0.049 8.491 1.007 71.559 
Anti-dsDNA ever 0.206 0.375 0.082 1.713 
Anticardiolipin ±Lupus 
anticoagulant 0.359 0.344 0.035 3.356 
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Maternal medications ever taken during pregnancy 
Steroids 0.379 0.506 0.111 2.304 
Hydroxychloroquine 0.809 1.205 0.265 5.486 
Azathioprine  0.909 0.908 0.173 4.775 
Aspirin 0.117 0.297 0.065 1.357 
Heparin 0.803 1.236 0.234 6.518 
Obstetric/Perinatal 
IUGR 0.559 1.942 0.210 17.950 
Pregnancy duration 0.896 0.983 0.757 1.276 
Birth weight 0.610 0.765 0.273 2.140 
Log of child age at entry 0.410 1.319 0.682 2.552 
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Infection 
Univariate analysis demonstrated significant associations between infection and 
azathioprine, and aspirin, as demonstrated in Table 12. 
Table 12 - Infection univariate analysis 
Suspected Risk factor for 
Infection  
 
P value OR 95% CI 
min  
95% CI 
max 
Maternal Risk Factors/Characteristics 
Maternal Ethnicity 
(Caucasian Vs all others) 0.226 1.933 0.665 5.620 
Maternal Disease characteristics 
Previous Renal biopsy 0.386 1.342 0.690 2.612 
Hypertension out of pregnancy 0.897 0.950 0.440 2.054 
Anti-phospholipid syndrome 0.238 0.514 0.170 1.554 
Maternal Antibodies     
Anti-dsDNA ever 0.432 1.278 0.692 2.360 
Anticardiolipin ±Lupus 
anticoagulant 
0.784 0.920 0.509 1.665 
 
Maternal medications ever taken during pregnancy 
     
Steroids 0.294 1.355 0.768 2.391 
Hydroxychloroquine 0.778 0.925 0.536 1.596 
Azathioprine ever 0.002 2.402 1.364 4.232 
Aspirin 0.038 2.038 1.041 3.991 
Heparin 0.110 1.652 0.893 3.056 
Obstetric/Perinatal 
Hypertension during pregnancy 0.721 0.874 0.417 1.831 
Pre-eclampsia 0.540 0.727 0.262 2.016 
IUGR 0.166 1.800 0.784 4.133 
Pregnancy duration 0.132 0.929 0.843 1.023 
Birth weight 0.894 1.028 0.686 1.539 
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A stepwise backward regression model was used to assess infection, using the following 
variables: pregnancy duration, birth weight, azathioprine ever, steroids ever, IUGR, anti-
dsDNA ever, anti-cardiolipin IgG/IgM or lupus anticoagulant, pre-eclampsia, hypertension 
out of pregnancy, antiphospholipid syndrome, maternal ethnicity (Caucasian versus all 
other), log of child’s age at entry, heparin ever, aspirin ever and previous renal biopsy. It 
was proposed that there will be greater than one factor contributing to infections in 
children, so both statistically significant and insignificant variables of clinical importance 
were included in the model to assess their potential effects.  
 
In a smaller more specific and robust model we adjusted for fewer variables; pregnancy 
duration, azathioprine ever, steroids ever, IUGR, anti-dsDNA ever, maternal ethnicity 
(Caucasian vs all others), aspirin or heparin ever and previous renal biopsy. Although on 
univariate analysis aspirin and azathioprine use during pregnancy and/or breastfeeding was 
significant, they are likely to be a surrogate marker for more severe disease. The only 
significant predictors of infection on stepwise backward regression were birth weight 
(p=0.027) and aspirin (p=0.037).  Aspirin is likely to be a predictor of low birth weight, as 
is likely to be associated with more serious maternal disease.  Gestational age and 
azathioprine were the last factors to fall out of the model. 
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Developmental problems 
A composite outcome of development delays and /or Attention Deficit Disorder and/or 
special schooling and/or special needs was used, as the frequency rate of individual 
outcomes were low. The only statistically significant variable identified on univariate 
analysis was the age of the child at entry into the study as shown in Table 13. The log of 
the child’s age was used, as data was not normally distributed. 
Table 13- Developmental problem Univariate analysis 
Suspected risk factors for 
Developmental problems as a 
composite outcome 
P value OR 95% CI 
min  
95%CI  
max 
Maternal Risk Factors/Characteristics 
Maternal Ethnicity 
(Caucasian Vs all others) 0.724 0.829 0.291 2.355 
Maternal educational needs 0.521 0.951 0.815 1.109 
Maternal ever smoking 0.305 0.511 0.142 1.844 
Maternal Disease characteristics 
Previous Renal biopsy 0.115 4.303 0.702 26.368 
Hypertension out of pregnancy 0.387 1.677 0.520 5.404 
Anti-phospholipid syndrome 0.445 0.448 0.057 3.508 
Maternal Antibodies 
Anti-dsDNA ever 0.612 0.759 0.262 2.202 
Anticardiolipin ±Lupus anticoagulant 0.614 0.739 0.228 2.393 
Maternal anti-Ro 0.514 1.471 0.461 4.687 
Maternal anti-La 0.290 1.951 0.565 6.735 
Maternal anti-Ro and/or anti-La 0.596 1.368 0.429 4.359 
Maternal medications ever taken during pregnancy 
Steroids 0.967 0.979 0.362 2.652 
Hydroxychloroquine 0.148 0.470 0.169 1.307 
Azathioprine  0.660 1.259 0.450 3.521 
Aspirin 0.263 0.564 0.207 1.536 
Heparin 0.498 0.643 0.179 2.307 
Obstetric/Perinatal 
Hypertension during pregnancy 0.606 0.671 0.147 3.053 
Pre-eclampsia 0.577 0.556 0.071 4.373 
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A multivariate analysis using stepwise logistic regression used the following variables: 
hydroxychloroquine, steroid, azathioprine aspirin and log of age at entry. The only variable 
that remained significant was the age at entry into study, OR 2.212, p<0.0001 (95%CI 
1.231-3.973).  There is no evidence in this study that any of the drugs studied had any 
detrimental effect, in fact hydroxychloroquine was the last to drop out in this model, and 
looked as if it might have protective properties, OR 0.699, p=0.508 (95%CI 0.242-2.020). 
 
. 
IUGR 0.904 1.099 0.238 5.080 
Pregnancy duration 0.981 1.022 0.835 1.203 
Birth weight 0.683 0.866 0.435 1.725 
Log of child age at entry 0.008 2.227 1.238 4.007 
Child Gender 0.750 0.850 0.314 2.301 
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Discussion 
 
This study is one of the largest studies of long term outcomes of children born to mothers 
with SLE up to the age of 17. In total data were analysed for 285 children, born to 199 
women.  The long term outcomes assessed were congenital anomalies, CHB, infection 
requiring hospital management and developmental problems. The rates of congenital 
anomalies as defined by EUROCAT and of complete CHB were both 2%. Infection 
requiring hospital management was reported in 69/274 (25%). There were very few 
developmental problems reported; development delay (5%), special needs (2%), attention 
deficit disorder (1%) and special educational needs (2%). Prior to discussing the long term 
outcomes in more detail, the characteristics of the population will be reviewed. 
 
 
Maternal Characteristics  
There were several differences between the data in this study and the general population 
data which will be discussed. The average age of mothers at delivery in this study was 32, 
which  was slightly older than the combined English and Welsh national average age of 
29.5 years in 2010 (158).  Lupus mothers were also found in a US study to be significantly 
older at 30, compared to those in the general population 27.5, p<0.001 and a Norwegian 
study 29.4 compared with 27.7, p<0.001 (25;25;159). The patient ethnicity proportions in 
the lupus groups differed in our study compared to a US study, this study had a lower 
proportion of African patients 11% compared to 20%, and an increased proportion of white 
patients 67% compared to 55% (25). 
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This study found that 4% of women smoked during pregnancy, in contrast 13% women 
who gave birth in England in 2011/12 reported smoking during their pregnancy(158). This 
is very reassuring in view of the link between smoking and poor pregnancy outcomes. A 
US and Norwegian study found no differences between women with lupus and those in the 
general population who smoked (25;159). 
 
In total 17% of mothers in this study drank alcohol, normally between 1-3 units per week, 
with only one mother drinking 5 units per week. Our results demonstrated 100% of women 
consumed no to moderate amounts (3–7 glasses/week) of alcohol during pregnancy 
compared to 95.5%, in a recent UK study (160).No differences in excess alcohol 
consumption were demonstrated in lupus patients compared to the general population in 
the literature(25).  
 
Our data identified that mothers who were taking azathioprine during pregnancy, were 
significantly older at delivery. It is likely that this group of patients had to wait for the 
disease to be stable, on drugs compatible with pregnancy. This is consistent with previous 
studies reporting that mothers with SLE have smaller families, later in life (14-17). 
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Outcomes of Pregnancy 
 
Caesarean section 
The English average for emergency and elective caesarean sections was 24% over 2010-11 
in comparison 37% of the women in our study required a caesarean section(158) . This 
may in part attributable to a difference in policy in many specialist obstetric clinics that 
treat women with lupus, inducing SLE pregnancies at thirty-eight weeks, due to the 
increased risk of stillbirth, which is not standard practice in the national population.  
Data was not routinely collected on any pregnancies prior to the fulfilment of a minimum 
of four ACR criteria, so it was not possible to assess if the higher rate of caesarean sections 
compared to the normal population was due to previous caesarean section and/or induction. 
However a previous caesarean does not preclude a vaginal delivery in a subsequent 
pregnancy, guidelines from the royal college of obstetricians and gynaecologists advises 
that vaginal birth after caesarean section can be safely considered on a case by case basis 
for both spontaneous and induced deliveries(161) 
The higher risk of caesarean sections in lupus patients, OR of 1.7, compared to the general 
population was also identified in a US Nationwide Inpatient Sample (NIS) study reviewing 
four years of data(25). A Norwegian study also identified a twofold increased risk of 
caesarean in first and subsequent deliveries when compared to the general population(159). 
A Canadian study which also compared SLE patients to the general population, found that 
the increased OR (3.47) for caesarean was maintained after adjustment for dysfunctional 
labour, instrumentation and previous caesarean section(162).  
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IUGR and Pre-eclampsia 
The rate of IUGR in our study at 4% (12/270) for the not severe enough to be induced 
group and 7% (19/270) in the severe enough to be induced group. The overall rate of 
IUGR reported was 12%, with no significant differences between pregnancies with 
hydroxychloroquine or azathioprine exposure. IUGR is commoner in SLE patients 
compared to the general US population, 5.6% versus 1.5%, p<0.001(25;159). IUGR was 
present in a higher proportion of patients in this study, which may be due SLE patients 
being recruited from specialist centres, who tend to have patients with more severe disease.  
Pre-eclampsia was reported at 4% (12/270) for the not severe enough to be induced group 
and 7% (19/270) in the severe enough to be induced group in this study.  Pre-eclampsia 
was found to be commoner in SLE pregnancies than the general population in several 
studies (25;159;162). The overall rate of pre-eclampsia in this study was 11% which is 
comparable to rates reported in Canadian study (9.5%) and a Norwegian study reported a 
rate of 14.7% in first births and 10.3% in subsequent births(159;162). However a US study 
reported an increased rate of 22.5%(25).The pre-eclampsia rate in our study was lower 
than expected, possibly due to aspirin being given to over 70% of patients. These data are 
very interesting and would be worthy of testing in a prospective study.  
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Child Demographic Data 
Gestational age and Birth weight 
 
The median gestational age in this study was 38 weeks with a range of 25-42 weeks, 73% 
of deliveries in this study were delivered between 37 and 41 weeks in comparison to 88.6% 
in the general UK population(163). There were no significant differences in mothers who 
were exposed or not exposed to hydroxychloroquine or azathioprine. A Canadian study 
also identified higher rate of preterm births compared to the general population, with 34% 
of deliveries in the SLE group occurring before 37 weeks gestation, compared with 24% in 
our study(162).  
The average birth weight in our study was 2.67kg, which is lower than the UK national 
data average of 3.3kg; this may be partially explained by the younger gestational age in our 
cohort (164;165). This discrepancy may also be due to the underlying SLE diagnosis and 
the different distribution of ethnicities in our cohort, which has a higher proportion of 
Afro-Caribbean and Asian patients due to the nature of SLE (164;165). Studies have 
demonstrated increased low birth weight infants born to mothers from Asian and Afro-
Caribbean groups compared to Caucasian (164;165).   
Our data are consistent with Canadian and US studies, which have also identified 
significantly more small for gestational age babies born to women with lupus than the 
general population. Interestingly the average birth weight of children born to mothers with 
SLE was significantly lower for both the first and subsequent pregnancies, 2.996kg and 
3.249kg respectively then the general population in a Norwegian study(159). However this 
was not specifically addressed in our study. 
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Congenital Anomalies 
 
The British Isles Network of Congenital Anomaly Registers (BINOCAR) is a group of 
regional and disease-specific registers collecting information about congenital anomalies 
occurring in England, Ireland, Scotland and Wales(166). They published data which 
looked at several UK registries which also used EUROCAT definitions in 2011(166). In 
2011, there were 5,718 cases with one or more congenital anomalies notified to six 
BINOCAR registers (East Midlands & South Yorkshire; Northern England; Oxfordshire, 
Berkshire & Buckinghamshire; South West England; Wessex; and Wales)(166). The birth 
prevalence was 2.19%, 1 in 46 total births(166).  
 
This is comparable to the congenital anomaly rate identified, 6/285 (2%), from our UK 
based cross sectional survey which will provide reassuring data with which to counsel 
women with SLE planning future pregnancies. The results from this study are also 
consistent with a smaller prospective and two recent large Canadian and Norwegian 
studies, that did not identify an increased rate of congenital anomalies in children born to 
mothers with SLE in comparison with the normal population (98;162;167). 
A weak association between IUGR and congenital anomalies was identified, on 
multivariate logistical analysis, which has also been confirmed in the general population 
(168). 
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Hydroxychloroquine 
 
Hydroxychloroquine has been demonstrated to be compatible with pregnancy in two 
systematic reviews (103;104). Many previous studies showed no increased risk of 
congenital anomalies as outlined in the section congenital anomalies and discussed in the 
introduction. This has increased hydroxychloroquine use in pregnancy and/or breast 
feeding, as demonstrated by the shorter disease duration in women who took 
hydroxychloroquine in our study.  A recently published observational comparative cohort 
study, collected prospective data on 114 pregnancies with hydroxychloroquine and 
identified a non significant increase in congenital anomalies when compared to 455 
controls, but this was not corrected for confounders (169). 
 
 
Azathioprine 
 
Several large recent studies have published data demonstrating no increase in congenital 
anomalies in the offspring born to women and/or men who took azathioprine during 
pregnancy to treat underlying IBD (170-174).  A large UK primary care record database 
that identified 1703 children born to mothers with IBD identified no increase in congenital 
anomalies when compared to controls or when specifically observing azathioprine/6-
mercaptopurine exposed children (171). Of interest recent studies have also demonstrated 
no increased risk of congenital anomalies following exposure to azathioprine in either 
parent, prior to or during pregnancies (170;173;175). Our study, combined with these 
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recent studies and previously published studies discussed in the relevant sections of the 
introduction have not demonstrated an increased risk of congenital anomalies in children 
where there was maternal or paternal exposure to azathioprine 
 
 
Neonatal Lupus Rash 
Cutaneous Neonatal lupus is reported to occur in 2-10% of children, born to mothers with 
anti Ro/SSA and anti La/SSB antibodies (32;119;176). The lesions often resolve within the 
first 3-6 months of life as maternal antibodies are cleared from the circulation. In total 42% 
of mothers had anti Ro/SSA and anti La/SSB antibodies and a neonatal rash was reported 
in 2% of cases. The rate of neonatal lupus rash in this study is lower than that reported in 
the literature, which is likely due to the condition being under recognised and reported by 
mothers.  
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CHB 
 
Complete heart block was reported in 2% of cases in this study, which is comparable to the 
1-2% reported in the literature (31-33;120;122;177). Several studies have recently looked 
into the possibility that hydroxychloroquine may prevent CHB. The possible relationship 
has been investigated based on the potential involvement of Toll-like receptor (TLR) 
signalling in the pathogenesis of neonatal lupus (NL). It was hypothesised that fetal 
exposure to hydroxychloroquine (HCQ), a TLR inhibitor, might reduce the risk of anti-
SSA/Ro/SSB/La antibody-associated cardiac manifestations of NL (178;179) 
 
There has been one case-control study which has found that the use of hydroxychloroquine 
in anti-Ro/SSA or anti-La/SSB autoantibody positive SLE women with a previous child 
with CHB did not result in a statistically significant reduced risk of CHB in subsequent 
pregnancies as shown in Table 11 (180). However hydroxychloroquine was found to be 
significantly associated with a reduction in recurrent CHB when all mothers were anti-
Ro/SSA or anti-La/SSB autoantibody positive, but did not necessarily have a diagnosis of 
SLE (181).  A retrospective review of women with anti-Ro antibodies, who did not 
necessarily have a diagnosis of SLE found that maternal treatment with either 
hydroxychloroquine or daily low-dose prednisone throughout pregnancy may provide a 
protective effect against CHB(182). The key findings of the studies recently published in 
the literature are outlined below in Table 11. 
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Our study did not identify a protective effect of hydroxychloroquine against complete heart 
block, but our study did not look at reoccurrence, due to the low frequency rate. 
Furthermore in our study approximately 40% of our cohort had anti-Ro and/or LA 
antibodies, in contrast to these previous studies, which exclusively recruited antibody 
positive women.  
 
The logistic multivariate analysis performed in our study identified that anti-La antibodies 
had the strongest association with CHB. There have been conflicting studies in the 
literature regarding the pathogenic role of anti-Ro and anti La antibodies individually in 
fetal heart block (183-185). This study and another recent study, suggested a potential role 
of anti-La antibodies, which were identified to bind to myocytes in fetal heart tissue in a 
smaller study (184;185). However a larger more recent study identified that cardiac 
complications of neonatal lupus were associated with the concentration of anti-Ro 
antibodies, irrespective of the presence of anti-La antibodies(182). This is an area of 
research that requires further study to confirm the potential associations. 
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Table 14 - Key findings of recently published CHB literature 
Study Study Type Antibodies Disease OR CHB in 
HCQ group 
95% CI p Value 
1. Izmirly. 
ARD. 2010 
Case Control 
N=201 
Anti-
Ro/SSA 
&/or anti-
La/SSB  
SLE only OR = 0.46 
Any CHB 
0.18-
1.18  
p=0.10 
2. Izmir. 
Circulation. 
2012 
Retrospective 
N=257 
Anti-
Ro/SSA 
±anti-
La/SSB  
Any OR = 0.23 
Recurrence 
0.06–
0.92  
p=0.037 
3. Tunks. 
AJOG. 2013  
Retrospective 
N=33 
Anti-
Ro/SSA  
Any OR=0.14 
Any CHB 
0.002–
1.35 
p= 0 .09  
 
A recent Abstract from a Canadian single centre retrospective study confirmed the 
protective effect of maternal antimalarials in women with a diagnosis of SLE, cutaneous 
lupus, Sjogren's dermatomyositis or rheumatoid arthritis during pregnancy against 
CHB(185). A prospective study to address the potential beneficial effects of 
hydroxychloroquine against CHB is currently being undertaken(185). 
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Gender ratio  
Our study demonstrated no significant gender difference, the male to female ratio was 
128/157 (0.8), (p=0.75, 95%CI 0.31-2.3). Recent Canadian data, using physician billing 
and hospital databases suggested an increase in the male-to-female ratio in children born to 
women with SLE, which was also found in murine studies (186;187). The gender 
discrepancy may be due to the presence of anti-NMDAR (N-methyl D-aspartate) receptor 
antibodies, a subset of anti-dsDNA antibodies. An increased male-to-female ratio was 
noted in pregnant mice exposed to anti-NMDAR antibodies, as there was a marked loss of 
female fetuses compared to unexposed pregnant mice (186). 
 
 
However results combined from PROMISSE (Predictors of Pregnancy Outcome: 
Biomarkers in Antiphospholipid Syndrome and Systemic Lupus Erythematous) a multi-
centre, prospective study, and RRNL (Research Registry for Neonatal Lupus), a registry of 
families in which the mother has anti-SSA/Ro and/or anti-SSB/La antibodies and at least 1 
child with neonatal lupus did not identify a gender discrepancy, as did this UK data (188).  
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Infection 
 
This study identified that 69/274(25%) of children for whom data was available required 
hospital management for infection. A statistically significant increased infection rate was 
identified in children born to women who took azathioprine during pregnancy and/or 
breastfeeding. However following multivariate analysis, this rate was accounted for by 
duration of pregnancy and birth weight, which are also predictors of infection in the 
general population. In addition the increased frequency of infections seen in children who 
took aspirin during pregnancy remained significant after multivariate logistic regression. 
This is likely to be due to aspirin being a confounder for severity of maternal disease, 
rather than as a direct action of the aspirin itself. 
In contrast to our study findings, an abstract from a recent Canadian case control study, 
analysing medical databases of 507 women with SLE who had 721 children, and 5862 
matched healthy controls who had 8561 children, reported slightly more serious infections 
at a younger age, the risk remained higher in the offspring of SLE patients after 
multivariate analysis (adjusted HR 1.76, 95% CI 1.21, 2.56) (189). This may be because of 
differing study methodologies, but as the Canadian study has only been published in 
abstract format, it is difficult to make any detailed comparisons.  
 
A recent study which compared 15 women with IBD who took azathioprine (median 
dosage 150 mg/day) during pregnancy and/or lactation with 15 who did not, found no 
statistically significant difference in hospital admissions for infection(134). In contrast to 
this study the number of children who were hospitalised for infection in the IBD study, 
were higher in the group not exposed to azathioprine (6/15, 40%) compared with (3/15, 
89	  
	  
20%) in azathioprine exposed group, but this was not statistically significant (134). The 
discrepancy between this study and our study may be explained by the increased 
percentage of preterm or the longer follow up period, combined or individually, reported in 
the non azathioprine exposed group in the IBD study. Prematurity as previously discussed 
is a risk factor for childhood infections, and the older a child is the more chance they have 
had to acquire an infection requiring hospital management.    
Information Services Division Scotland, published discharge diagnosis for emergency 
admission for certain infections including intestinal infections, tuberculosis, viral 
meningitis, chicken pox and measles was 1, 103 per 100, 000 population(190). This was 
lower than  the rates reported in this study, but this may be as only certain infections were 
included, whereas this study included all infections(190). 
 
Several recent large population studies have looked into the outcome of late preterm birth 
with regard to infections. A study which assessed hospitalisations for nonspecific and 
bacterial infections in the general population during the first year of life by gestation found 
an increase in infection in infants with lower gestational age at birth (191).  This finding 
was also corroborated in a study, which found that emergency respiratory admissions, up 
to the age of five years reduced with every successive gestational week up to 40 to 42 
weeks (192). The discharge diagnoses studied were acute upper respiratory tract, influenza, 
pneumonia, acute lower respiratory tract infections, acute bronchiolitis and asthma (192). 
A Canadian population study established that late preterm infants had significantly 
increased risk of infectious disease, respiratory disease and hearing loss (193).  A 
preliminary Italian cohort study suggested that hospitalizations for lower respiratory tract 
infections were more frequent in lower gestation groups; 4.4% in 33-34 gestational week 
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group, 4.6% in 35-37 gestational week groups and 3.5% in infants born ≥38 weeks (194). 
Our study looked at any infections requiring hospital management; the numbers in our 
study were much smaller which may be why no association with gestational age was 
identified. 
 
Low birth weight in the general population has been linked to an increased risk of 
hospitalisation for respiratory including infections, during both adolescence and adulthood 
(130-132). 
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Developmental Problems 
 
Overall there was a low rate of all developmental problems whether analysed individually 
or combined. In total 6% (17/284) had developmental delay and/or attention deficit 
disorder and/or special schooling and/or special needs. Developmental delay was reported 
in 14/285 (4.9%), special needs in 7/285(2.5%), attention deficit disorder 3/285(1.1%) and 
the requirement for special schooling 6/285(2.1%). There was no statistical significant 
association identified with any maternal or child variables. Although autism was not 
specifically enquired about, it will be captured in the composite endpoint used. However 
an adequately powered prospective study would be needed to study any possible 
relationship.  
 
There is a potential association between developmental problems and autoimmune disease, 
specific antibodies and drugs which will be discussed in separate sections.  
 
Our results identified ADD in 3/285(1.5%) of the children, which is lower than the 
prevalence rates identified in a UK study using medication treated ADHD in children over 
six, adolescents and adults in primary care(195). The prevalence per 100, 000 in 6-12year 
was 9.2 (95% CI: 8.8–9.6) and 7.4 (95% CI: 7.0–7.8) in the 13–17  year age group (195).  
 
There was no significant difference in the frequency of developmental problems in 
children who were exposed or not to azathioprine during pregnancy and/or breastfeeding as 
shown in Table 8. 
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The number of events identified in our study was very low, as the median age of children 
at enrollment was 3.0 years, so developmental problems may not yet have been identified. 
Developmental problems will normally be identified in school aged children, in our study 
97/285 (34%) were five or over. Several studies in the literature have looked into the 
possible underlying mechanisms behind neurodevelopmental problems in the offspring of 
SLE patients, as outlined below. Further follow up of this cohort should help to define this. 
 
The protective effects of hydroxychloroquine during pregnancy may be due to its 
beneficial effects on the placenta in vitro studies of APS patient placentas(196). In this 
study hydroxychloroquine reversed the anti-phospholipid inhibition of trophoblast 
interleukin-6 secretion in addition to partially limiting anti-phospholipid inhibition of cell 
migration(196). However further research will need to be undertaken to assess the effect of 
hydroxychloroquine in vivo 
 
Parental Autoimmune disease 
A recent large population based cohort study found that the presence of any maternal 
autoimmune condition, including lupus, were  more likely in children with autism 
spectrum disorder (ASD) and developmental delay without autism (DD) than in 
controls(197). The largest study to date included 3,325 cases from a Danish registry, 
investigating autism and autoimmune conditions (198). The study observed an increased 
risk of ASDs in children with a maternal history of rheumatoid arthritis, coeliac disease 
and a family history of type 1 diabetes (198). This relationship is felt to be attributable to a 
combination of genetic background, prenatal antibody exposure or alteration in fetal 
environment during pregnancy (198).  
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A smaller Swedish registry study, that were linked to both biological parents, identified 
1237 cases and 30,925 controls(199).  Autism spectrum disorders were associated with 
parental autoimmune disease; maternal OR = 1.6 [95% confidence interval = 1.1–2.2] and 
paternal OR = 1.4 [1.0 –2.0](199). Several maternal autoimmune diseases  were 
significantly associated with autism, including type-1 diabetes, idiopathic 
thrombocytopenic purpura, myasthenia gravis, and rheumatic fever(199). SLE was not 
found to be significantly associated with autism in this study, but there were only 20 
women with SLE in this study, 2 of whom had a child with an ASD(199). 
 
 
Autoantibodies 
 
At present the precise mechanism underlying the relationship between children born to 
mothers with SLE and neurodevelopmental and learning disabilities is unknown. Animal 
studies have identified that maternal antibodies may contribute to abnormal 
neurodevelopment and congenital cortical impairment (200). 
A recent study which tested the serum of 2431 mothers of autistic spectrum children and 
653 controls for anti-brain antibodies via immunohistology on mouse brains(201). It 
identified mothers of autistic spectrum children were four times more likely to have brain-
reactive antibodies and of those with antibodies a higher prevalence of autoimmune disease 
especially SLE(201). This study provides evidence that there are increased brain reactive 
antibodies in the serum of mothers of autistic spectrum children, which may be associated 
with maternal autoimmunity(201). This suggests that a further avenue for research will be 
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to look into characterising these antibodies further to identify the potential pathogenicity of 
these antibodies on the developing brain(201). 
 
 
Anti-Ro/SSA and Anti-LA/SSB antibodies  
A study identified 26 children born to mothers with SLE, with an average age of 6.6 (range 
0.7-12.8)  and suggested a possible link between Ro/SSA antibodies and 
neurodevelopment(202), Although IQ was normal in all children, Sequential Processing 
scores were significantly lower in the nine children with Ro/SS-A-positive mothers, 
compared with the 17 negative mothers. However it is of note that there was also an 
increased incidence of other potential confounders; IUGR, low birth weight and 
prematurity (202). 
 
In a study which looked at the outcome of 114 children born to mothers with Ro/La 
antibodies, 63 of the children had CHB and the remaining 62 children were siblings 
without CHB(203). Children were born between 1980 and 2009, with a median follow up 
time of 13 years (25th–75th percentile: 8.2–17.5 years)(203).  This study identified the 
following significant relationships; increased impaired motor skill development in boys (p 
< 0.001) and preterm children  (p < 0.001), increased learning impairment in maternal SLE 
(p < 0.005), increased attention deficits with both maternal SLE (p < 0.05) and CHB (p < 
0.05)(203). 
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Antiphospholipid Antibodies 
 
Data presented at the American College of Rheumatology analysed two hundred and nine 
pregnancies in one hundred and twelve women, using this UK questionnaire in the 
Baltimore lupus centre in the USA, (204). No autoantibody was statistically significantly 
associated with attention deficit disorder or with dyslexia, but the frequency of 
anticardiolipin was increased in both conditions(204). 
 
Studies of children with no known autoimmune diagnosis have found that children with a 
known diagnosis of autism have elevated levels of anti-phospholipid antibodies (anti-
cardiolipin, β 2-glycoprotein 1, and anti-phosphoserine antibodies) compared with age 
matched healthy controls and children with non autistic developmental delays(205).  
 
The largest study to date looking at the long term outcomes of children born to women 
with antiphospholipid antibodies is the European registry of babies born to mothers with 
antiphospholipid syndrome (52;206;207). Intermediatory results demonstrated transfer of 
autoantibodies to the neonate, which were confirmed in subsequent analysis of the data 
(52;206;207). Antiphospholipid antibody placental transfer was identified in the 
preliminary analysis on the follow-up of 141 babies, in 20, 25 and 43% of cases for lupus 
anticoagulant, anticardiolipin and anti-β2-glycoprotein I antibodies, respectively(52).  
 
Recently the European registry group published 5 year follow up data on 134 children, 
born to 133 women with antiphospholipid syndrome and of these 18 also had a diagnosis 
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of SLE (207). The four neurocognitive problems identified were (autism, hyperactive 
behaviour, feeding disorder with language delay and axial hypotony with psychomotor 
delay (207).  
 
A subsequent study which looked at the offspring of women with primary 
Antiphospholipid syndrome (n=36) and SLE without antiphospholipid syndrome (n=12), 
identified 3 case of autism, which were all from the primary Antiphospholipid syndrome 
group(208). All these pregnancies were treated and no adverse obstetric events including 
IUGR were present, APS antibodies were implicated as during follow up all these children 
had persistent anti-β2 GPI antibodies, but with no antiphospholipid features of APS or 
thrombus(208). 
 
A study which looked at the neurodevelopment in 17 children born to mothers with 
primary antiphospholipid syndrome, identified 4 children with learning difficulties on 
formal testing(209). However they also alluded to the presence of other potential risk 
factors including prematurity, that could interact with maternal antiphospholipid 
antibodies(209). 
 
In contrast a study, which reviewed the outcomes of 26 children, aged between 6 months 
and 12 years, born to women with SLE, found no relationship between the presence of 
maternal antiphospholipid serology (n=10) and intelligence test scores(202). Our study 
also did not demonstrate an association between developmental problems and 
antiphospholipid syndrome.  
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Azathioprine 
 
Our study did not identify an increase in developmental delays in contrast to a study using 
the same standardised questionnaire in the United states (US) (210). The US study 
suggested that there may be an association between in utero azathioprine exposure and an 
increased requirement for special education requirements, assessed by an appropriately 
qualified professional(210). However there were only 13/60 (22%)  children exposed to 
azathioprine at a single centre in the US in contrast to 85/287 (30%) children in this study 
from multiple UK centres, but the children in the US study  had a higher median age of 5.7 
years in comparison to 3.2 years in our study(210). In addition there was a higher 
proportion of renal disease in the US group 45%, comparison to 23% in this study 
cohort(210).  The authors do state that the study does not establish sufficient risk, and warn 
that untreated disease in pregnancy is a risk in itself for adverse maternal and fetal 
outcomes(210). 
 
 
A recent study from the IBD literature compared 15 exposed and 15 nonexposed children 
with a median and range ages of 3.3 (0.6–6) and 4.7 (1.1–8.6) respectively, all the children 
had appropriate mental and physical development (134;134). Although the numbers in the 
IBD study were smaller than this study, it is of interest that the median age of children in 
our study was 3.0, (range of 0-17), but the range was wider in our study (134). 
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Other relevant risk factors linked to developmental delay in the general population include 
autism and childhood infection(198;211) as well as late preterm birth (34-37 weeks 
gestation) and cerebral palsy(212). A recently recognised subgroup of preterm babies, are 
those born between 34 and 36 weeks (late preterm), which account for approximately 70% 
of all preterm deliveries (213;214). Several recent studies have looked at the educational 
and neurodevelopmental outcomes of children born late preterm and have identified 
increased problems when compared to children who were born at term (215-224). In this 
study the mean gestational age was 36.3 week (sd 4.13), a substantial proportion were late 
preterm, and it may have been that because a lot of children in our study were under 5 and 
did not undergo formal neurodevelopmental assessment, as in the majority of these studies 
in the general population that no increase in developmental problems were identified.  
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Limitations 
 
This study had several methodical considerations. Data were collected retrospectively, 
which increases the possibility of bias due to recall or loss to follow up. However patients 
were not aware of the specific hypothesis being examined in this study. The data was self-
reported and confirmed with the medical records when possible, but many were not 
confirmed by GPs. Unfortunately it was difficult to ensure that GPs respond to letters 
requesting information about children, probably as no payment for their contribution to this 
research study was available.  
Data was not collected on disease activity or on prednisolone dose throughout pregnancy, 
so the effect of longitudinal patterns of disease activity and medication dose on maternal 
and fetal complications could not be assessed.  
 
Another limitation was that relatively few developmental problems were reported in this 
cohort, which may have confined the identification of potential risk factors in this cohort. 
This questionnaire has been used internationally and international analyses of these data 
have been planned in the future to overcome the limitations of analysing relatively few 
events in this cohort. However validated instruments were not used across the whole 
cohort, which would have helped to account for geographical differences in identification 
and referral of childhood outcomes such as infection and developmental problems. The 
median age of children in our cohort was relatively young, 3.3 years, which may have led 
to an underestimation of developmental problems, as they have not yet reached school age. 
This bias may have been introduced, as pregnancy data were more readily available for 
younger children.  
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In retrospect it would have been ideal to collect data on maternal pregnancy and post-
partum disease activity, as maternal health can effect childhood development and how 
readily parents seek healthcare advice. More detailed maternal socioeconomic data, 
including maternal and paternal occupation, would have allowed its inclusion in 
multivariate analysis, as a potential confounder for child health. These considerations 
would be important in a future prospective study. 
Pregnancy losses (miscarriages or still birth) were not addressed in this study as the main 
aim of this study was to investigate the long term outcomes of live born children. There 
were also methodological limitations in collecting pregnancy data, as they were collected 
retrospectively and inconsistently across the centres as women had pregnancies in other 
hospitals.  
Data were not collected on maternal use of fluorinated steroids, which cross the placenta, 
for prematurity and/or myocarditis due to CHB prior to delivery, as this will be difficult to 
accurately recall retrospectively. A prospective study would be better able to address this 
potential confounder for developmental delay 
 
Analyses not carried out:  
There were a wide range of children recruited, and medical practice has changed over the 
years, so carrying out an analysis taking this into consideration would have allowed 
correction for this. Furthermore we did not control for the number of children born to each 
mother. In addition developmental problems will usually become evident when children 
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start formal education at the age of 4-5, so an analysis looking at children over five would 
have helped to correct for this.  
However this study reviewed a well characterised group of SLE patients recruited from 
specialist UK centres.  All the centres form part of the BILAG Group. It is believed that 
the data provided covers a broad spectrum of disease, as demonstrated by the drug data, 
20% of women took no DMARD, including prednisolone, during pregnancy and/or 
breastfeeding (table 17). 
 
Further development 
 
A meta-analysis of the international data is planned, which may be able to provide more 
information on the incidence and possible risk factors for maternal and fetal complications.  
 
However based on the results of this UK analysis, this project could be further developed 
by setting up a prospective registry, which would overcome the issues of recall bias and the 
likely too few events for a case control study.   
 
A future prospective study would allow the associations identified in this study, to be 
studied further. However the study would need to be set up to regularly review children for 
a minimum of five to ten years after enrolment to enable the identification of 
neurocognitive disorders. A further study with increased numbers would also be able to 
address any potential protective effects of hydroxychloroquine on developmental delays 
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Summary  
Data was presented on 285 children born to 199 mothers after a diagnosis of SLE that met 
all the inclusion and exclusion criteria. Overall the data from this study provided reassuring 
evidence when looking at the three key long term outcomes of interest congenital 
anomalies infection and developmental problems. Once controlled for confounders there 
was no evidence that any of the drugs had a detrimental effect.  The risk factors for an 
infection requiring hospital management are those of the general population, specifically 
birth weight. Aspirin appeared to be a risk factor, but this is likely to be due to the 
underlying maternal disease being an indication for aspirin use.    
 
Overall the results from this study are very encouraging, and can provide reassurance, 
when counselling mothers with SLE regarding long term outcomes of children. In addition 
our study will provide data to support physicians, using drugs and treating these diseases in 
pregnancy.  
 
 
 
 
103	  
	  
Appendix 
Congenital Anomaly Analysis Plan 
 
Univariate analysis will be performed to use the following variables which are suspected 
risk factors,  
 
Maternal Risk Factors/Characteristics 
Maternal Ethnicity 
(Caucasian Versus all others)  
 
Maternal Disease characteristics 
Previous Renal biopsy 
Hypertension out of pregnancy 
Anti-phospholipid syndrome 
Maternal Antibodies 
Anti-dsDNA ever 
Anticardiolipin ±Lupus anticoagulant 
 
Maternal medications ever taken during pregnancy 
Steroids 
Hydroxychloroquine 
Azathioprine  
Aspirin 
Heparin 
 
Obstetric/Perinatal 
Pre-eclampsia 
IUGR 
Pregnancy duration 
Birth weight 
Log of child age at entry 
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CHB Analysis plan 
The following variables will be assessed using univariate analysis: 
 
Maternal Risk Factors/Characteristics 
Maternal Ethnicity 
(Caucasian Versus all others) 
 
Maternal Disease characteristics 
Previous Renal biopsy 
Maternal Antibodies 
Anti-Ro 
Anti-La 
Anti-Ro and/or La 
Anti-dsDNA ever 
Anticardiolipin ±Lupus anticoagulant 
 
Maternal medications ever taken during pregnancy 
Steroids 
Hydroxychloroquine (possibly protective) 
Azathioprine  
Aspirin 
Heparin 
 
Obstetric/Perinatal factors 
IUGR 
Pregnancy duration 
Birth weight 
Log of child age at entry 
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Infection Analysis Plan 
 
Infection requiring hospital management, in Accident & Emergency departments or as an 
in or outpatient will be studied to account for the differences in individual hospital 
admission policies and differing ages of children within the study.  
 
The suspected risk factors assessed for infection were:  
 
Maternal Risk Factors/Characteristics 
Maternal Ethnicity 
(Caucasian Versus s all others) 
 
Maternal Disease characteristics 
Previous Renal biopsy 
Hypertension out of pregnancy 
Anti-phospholipid syndrome 
Maternal Antibodies 
Anti-dsDNA ever 
Anticardiolipin ±Lupus anticoagulant 
 
Maternal medications ever taken during pregnancy 
Steroids 
Hydroxychloroquine 
Azathioprine ever 
Aspirin 
Heparin 
 
Obstetric/Perinatal variables 
Hypertension during pregnancy 
Pre-eclampsia 
IUGR 
Pregnancy duration 
Birth weight 
Log of child age at entry 
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Developmental Problems Analysis Plan 
 
Univariate analysis will use a combination of any one of the 4 variables below, as a 
composite outcome: 
 
Development Delay 
Special Needs 
Special schooling 
Attention Deficit Disorder 
 
 
 
The following suspected risk factors for developmental problems as a composite outcome 
will be assessed: 
 
Maternal Risk Factors/Characteristics 
Maternal Ethnicity 
(Caucasian Vs all others) 
Maternal educational needs 
Maternal ever smoking 
 
Maternal Disease characteristics 
Previous Renal biopsy 
Hypertension out of pregnancy 
Anti-phospholipid syndrome 
Maternal Antibodies 
Anti-dsDNA ever 
Anticardiolipin ±Lupus anticoagulant 
Maternal anti-Ro 
Maternal anti-La 
Maternal anti-Ro and/or anti-La 
 
Maternal medications ever taken during pregnancy 
Steroids 
Hydroxychloroquine 
Azathioprine  
Aspirin 
Heparin 
 
Obstetric/Perinatal factors 
Hypertension during pregnancy 
Pre-eclampsia 
IUGR 
Pregnancy duration 
Birth weight 
Log of child age at entry 
Child Gender 
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Supplementary Tables  
 
Additional Maternal Demographics 
 
The ethnic mix of patients in this study is representative of a typical lupus cohort.  The 
maternal education, smoking and alcohol consumption during pregnancy in those that took 
alcohol are outlined in Table 15. No mothers reported using illicit drugs during pregnancy.  
 
Table 15 - Additional maternal demographics 
 
Characteristic Mean/median or Number (%) SD/Other Information 
Ethnicity 
n=275 
Afro-Caribbean = 30/275 (11%) 
Asian= 44/275 (16%) 
Caucasian = 183/275 (67%) 
Oriental = 4/275 (1%) 
Other=12/275 (4%) 
Hispanic = 2/275 (1%) 
 
Maternal Education 
(Years) 
Median=16 
Available in 250 
Range 5-30 
IQR 13-18 
Pregnancy number 1st= 52% 
2nd =26% 
3rd = 15% 
4th = 49% 
5th = 1% 
6th= 1% 
9th = <1% 
NK = 1% 
Average = 2 
Range = 1-9 
Smoking – Current, Ex-
smoker or Non smoker 
Smoking Status NK = 16 
Never Smoked = 188 
Ex-Smoker = 64 
Current Smoker = 18 
Smoking during 
pregnancy=11 
Alcohol (During 
pregnancy) 
Alcohol during pregnancy=48 
No alcohol during pregnancy=237 
Not known =2 
Average no of units=2 
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Medications 
 
 
Maternal medications ever taken throughout conception, pregnancy and breast feeding (if 
applicable) are summarised in table 16. When the data were reviewed, it was identified that 
in those who chose to breast feed, most women continued drugs taken during pregnancy. 
This meant that the numbers between only pregnancy exposed and breast exposures were 
not sufficiently different for this analysis to be relevant. The majority of women took 
aspirin and over half took prednisolone and hydroxychloroquine during pregnancy and/or 
breast feeding, as shown in Table 16	  -­‐	  Maternal	  Medication. Only one baby was exposed 
to mycophenolate throughout pregnancy and three were exposed to ciclosporin, as 
demonstrated in Table 16	  -­‐	  Maternal	  Medication. 
 
Table	  16	  -­‐	  Maternal	  Medications
SLE medications Ever during 
pregnancy and/or 
breastfeeding 
Number (%) 
Never during 
pregnancy 
Number (%) 
Aspirin 200/282 (71) 82/282 (29) 
Heparin 69/281 (25) 212/281 (75)  
Prednisolone 169/285 (59) 116/285(41) 
Hydroxychloroquine 150/285 (53) 135/285 (47) 
Azathioprine 88/287 (31) 198/287 (69) 
Mycophenolate Conception only= 2 
Throughout 
pregnancy=1 
 
Ciclosporin 3 conception & 
throughout pregnancy 
 
Tacrolimus Nil  
Methotrexate Nil  
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Maternal Drug Combinations 
 
 
 
 
Table 17 summarises the drug combinations mothers took during conception, pregnancy 
and breast feeding (if applicable). Mothers were again classified as taking a drug if they 
had ever taken the drug, to accurately capture the possible effects of drugs on maternal, 
fetal and long term child outcomes. It is of note that a fifth of women took no DMARD 
during pregnancy. The commonest drug combination was azathioprine and prednisolone 
with or without hydroxychloroquine as shown in Table 17. Azathioprine was almost 
always co-prescribed with prednisolone.  
 
 
 
Table	  17 - Maternal drug combinations 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Aza=Azathioprine, Pred=Prednisolone, HCQ=Hydroxychloroquine, DMARD=Disease 
Modifying Anti-Rheumatic Drug 
Drug Combination Yes 
% 
No 
% 
AZA alone  2 98 
AZA & HCQ & no pred  2 98 
AZA & no pred  4 96 
AZA & Pred & HCQ  14 86 
AZA & Pred  ±HCQ  26 74 
No DMARD  20 80 
HCQ alone  16 84 
Pred alone  12 88 
Pred & HCQ only  20 80 
Pred & AZA only 13 87 
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Maternal Antibody Status 
 
 
 
The presence of maternal lupus and anti-phospholipid antibodies individually and 
combined are summarised in table 15.  The majority of women were not positive for 
antiphospholipid antibodies, either individually or combined as shown in Table 18. In total 
66% of mothers had ever had dsDNA and under half (42%) had anti Ro and/or anti-La 
antibodies as demonstrated in Table 18. 
Table 18 - Maternal Antibody Status
Antibody Present 
Number 
(%) 
Not present 
Presence Antiphospholipid 
antibodies 
I.e. LAC±ACL IgG±IgM  
123/251 
(49) 
128/251 
(51) 
Lupus anticoagulant 93/260 (36) 166/260 
(64) 
Anti-cardiolipin IgG 62/251 (25) 189/251(75) 
Anti-Cardiolipin IgM 38/251 (15) 213/252 
(85) 
Anti-Cardiolipin IgG and/or IgM 67/251 (27) 184/251 
(73) 
dsDNA 178/269 
(66) 
91/269 (34) 
RNP and/or Sm 72/266 (27) 197/266 
(73) 
Anti-Sm 40//263 
(15) 
223/263 
(85) 
Anti-Ro 106/262 
(40) 
156/262 
(60) 
Anti-La 53/260 (20) 207/260 
(80) 
Maternal Ro and/or La antibodies 110/261 
(42) 
 
151/261 
(58) 
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Additional child Demographic Data 
 
 
The median and range age of child at entry into the study were 3.26(0-17), as shown in 
Table 19, the majority (67%) of children were under five when data was collected. In total 
61% of children were born vaginally, of these 11% required instrumentation with forceps 
or ventouse, as shown in Table 19. 
 
 
Table 19 – Additional child demographics 
 
Characteristic N(%) Range 
Child age at entry to study 
(n=285) 
0-<12 months = 69/285 (24) 
12 months-<24months = 34/285 (12) 
24 months to <5yrs = 85/285 (30) 
5 yrs - <10 yrs = 53/285 (19) 
10yrs to <15yrs = 40/285 (14)  
15yrs to 17years = 4/285 (1) 
 
 
 
Range 0-17 
IQR 1.3-6.9 
Median 3  
Mode of delivery 
(n=283) 
Vaginal=141/283 (50) 
Forceps/Ventouse=31/283 (11) 
C section= 111/283 (39) 
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Infections sub divided  
 
 
In total 69 out of 274 children for whom data was available required a hospital 
management for infection, the number and percentage of children in each age group are 
illustrated Table 20.  The highest percentage and number of infections was seen in the 
under 5 group. Hospital management was used rather than in and/or outpatient admissions 
to account for the different geographical and age admission criteria. 
 
Table 20 - Infection by age 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Age  Total 
number 
analysed 
N=274 
No of pts 
with 
variable 
No (%) 
No of pts  
without 
variable 
No (%) 
0-1 63 11(17) 52(83) 
1-2 33 9 (27) 24 (73) 
2-5 83 29 (35) 54 (65) 
5-10 53 12 (23) 41 (77) 
10-15 37 7 (19) 30 (81) 
15-17 4 1(25) 3(75) 
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 Developmental problems subdivided by age 
	  Table	  21	  -­‐	  Developmental	  problems	  overall	  and	  subdivided	  by	  age	  
The	  frequency	  of	  developmental	  problems	  is	  demonstrated	  for	  the	  group	  overall	  and	  subdivided	  
by	  age.	  There	  were	  very	  few	  if	  any	  children	  who	  had	  a	  problem	  identified	  below	  the	  age	  of	  two.	  
	  
	   Age	   Present	  
No(%)	  
Not	  Present	  
No(%)	  
Developmental	  delay	   All	   14/285	  (5)	   271/285	  (95)	  
0-­‐<12	  months	   0/69	   69	  
12	  months-­‐<24months	  	   2/34(6)	   32/34(94)	  
24	  months	  to	  <5yrs	   5/85(6)	   80/85(94)	  
5	  yrs	  -­‐	  <10	  yrs	   3/53(6)	   50/53(94)	  
10yrs	  to	  <15yrs	   3/40(8)	   37/40(92)	  
15yrs	  to	  17years	   1/4(25)	   3/4(75)	  
Special	  Needs	   All	   6/285(2)	   279/285(98)	  
0-­‐<12	  months	   n/a	   n/a	  
12	  months-­‐<24months	  	   1/69(1)	   68/69(99)	  
24	  months	  to	  <5yrs	   1/85(1)	   84/85(99)	  
5	  yrs	  -­‐	  <10	  yrs	   0	   53	  
10yrs	  to	  <15yrs	   2/40(5)	   38/40(95)	  
15yrs	  to	  17years	   2/4(50)	   2/4(50)	  
Attention	  Deficit	  Disorder	   All	   3/285(1)	   282/285(99)	  
0-­‐<12	  months	   0	   69	  
12	  months-­‐<24months	  	   0	   34	  
24	  months	  to	  <5yrs	   0	   85	  
5	  yrs	  -­‐	  <10	  yrs	   0	   53	  
10yrs	  to	  <15yrs	   2/40(5)	   38/40(95)	  
15yrs	  to	  17years	   1/4(25)	   3/4(75)	  
Special	  Educational	  Needs	   All	   6/285(2)	   279/285(98)	  
0-­‐<12	  months	   n/a	   n/a	  
12	  months-­‐<24months	  	   1/34(3)	   33/34(97)	  
24	  months	  to	  <5yrs	   1/85(1)	   84/85(99)	  
5	  yrs	  -­‐	  <10	  yrs	   0	   53	  
10yrs	  to	  <15yrs	   2/40(5)	   38/40(95)	  
15yrs	  to	  17years	   2/4(50)	   2/4(50)	  
	  
 
114	  
	  
LONG-TERM OUTCOMES IN SLE 
 
CENTRE No: ______ PATIENT ID: ______ DATE: _______ 
DEMOGRAPHIC DATA  (Hospital/research staff to complete from medical 
notes) 
 * not to be entered on database. For all items including race put NK if NOT 
KNOWN.     
First Name*  Home Telephone* 
Surname*  Work Telephone* 
Postcode  Country of Birth 
Unit No.  Occupation 
DOB  Years of Education 
RACE:1=Afro-Caribbean, 2=Asian, 3=Caucasian, 4=Oriental, 5= Other/mixed, NK=Not known 
RACE/ Mother:1=Afro-Caribbean, 2=Asian, 3=Caucasian, 4=Oriental, 5= Other/mixed or NK 
RACE/ Father:1=Afro-Caribbean, 2=Asian, 3=Caucasian, 4=Oriental, 5= Other/mixed or NK 
YEAR of ONSET (SLE 1st ARA):   YEAR of DIAGNOSIS (SLE 4th ARA):  
Marital Status:  Married / Single / Widowed / Divorced / Separated / Partner/Not known 
 
LUPUS FEATURES  
ARA Criteria Year of Onset 
Malar rash  
Discoid rash  
Photosensitivity  
Oral ulcers  
Arthritis  
Serositis  
Renal disorder  
Neurological disorder  
Haematological disorder  
Immunological disorder  
Antinuclear factor  
Ever Present Yes No Not measured Ever Present Yes No Not 
measured 
ACLG    Anti-Ro    
ACLM    Anti-La    
Anti-ds DNA    Anti-Rnp    
Lupus Anticoagulant    Anti-Sm    
PART A: MOTHER 
Renal Biopsy 
Yes/No/Not known 
WHO grade _____________ 
Date : ___________________ 
Comments on reverse of form 
HYPERTENSION – requiring 
treatment out of pregnancy? 
Yes/No/Not known  
HYPERLIPIDAEMIA– requiring 
treatment out of pregnancy?   
Yes/No/Not known 
Does the patient have *Anti-
Phospholipid Syndrome? 
Yes/No/Not known 
 If Yes Date diagnosed:  _______ 
*  Wilson WA et al (1999)  
   Arthritis Rheum 42: 1309-1311 
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CENTRE No: ______ PATIENT ID: ______  
Past Medical History     (Discuss this page with patient in clinic if 
necessary) 
 
Thyroid Disease     Yes/No/Not known If Yes, give year of diagnosis 
Type I - Diabetes Mellitus   Yes/No/Not known If Yes, gives year of diagnosis 
Pernicious Anaemia   Yes/No/Not known If Yes, give year of diagnosis 
Rheumatoid Arthritis   Yes/No/Not known If Yes, give year of diagnosis 
Other Yes/No/Not known  If Yes, give year of diagnosis 
Thrombosis    Yes/No/Not known If Yes, give year of diagnosis  
 
Number of pregnancies: [   ] Number of children born:  [   ] Any twins or multiple births:  Yes  / No 
 
Ever had a termination?  Yes/No/Not known If Yes, year(s): __________________  
Ever had a miscarriage?  Yes/No/Not known If Yes, year(s): __________________ 
Ever had a stillbirth?  Yes/No/Not known If Yes, year(s):  _________________ 
 
 
Family History  
 
Other family member(s) with SLE Yes/No/Not known - ____________________ 
Thyroid Disease   Yes/No/Not known - ____________________ 
Diabetes Mellitus   Yes/No/Not known - ____________________ 
Angina or Heart Attack   Yes/No/Not known - ____________________ 
High Blood Pressure   Yes/No/Not known - ____________________ 
High Cholesterol levels   Yes/No/Not known - ____________________ 
Anti-phospholipid Syndrome (Sticky 
Blood or Hughe’s Syndrome)  Yes/No/Not known - ____________________ 
Alcohol Intake 
Did you drink alcohol during any pregnancy?    Yes/No/Not known 
If Yes, how many units per week in which pregnancies (approximately)?    
 
Pregnancy 1 ______Pregnancy 2 ___ Pregnancy 3 ______Pregnancy 4 ______  
Pregnancy 5 _______Pregnancy 6 ______________ 
*Unit of alcohol is equivalent to the amount of alcohol in a half-pint (250ml) of beer, or a small glass of wine, or a single 
measure of spirits 
 
Smoking History 
Ever smoked cigarettes? Yes / No   Did you use in any recreational drugs in 
pregnancy?                              
Date Started: ______  Date Finished: _________ Yes/No/Not known 
Smoking during any pregnancy:  Yes/No/Not known If yes: which pregnancies? 
Pregnancy 1 ________________________  Pregnancy 1 _____________________ 
Pregnancy 2________________________  Pregnancy 2 _____________________ 
Pregnancy 3 ________________________  Pregnancy 3 _____________________ 
Pregnancy 4________________________  Pregnancy 4 ______________________ 
Pregnancy 5______________________   Pregnancy 5______________________ 
Pregnancy 6______________________   Pregnancy 6______________________ 
Others       ______________________   Others       ______________________  
If	  yes,	  please	  state	  which	  of	  these	  relatives:	  
mother,	  father,	  sister	  or	  brother	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CENTRE No: ______ PATIENT ID: ______PREGNANCIES (Information from medical notes) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1	   First Pregnancy Name of child:_______________________ 
DOB	  of	  child____________	  Gender:	  F	  	  /	  	  M 
Miscarriage:  Yes / No/ Not known 
Stillbirth: Yes / No/ Not known 
Slow Heart Rate:Yes / No/ Not known 
Weight @ birth: ________ or Not known  
Duration of Pregnancy: ______weeks  
 
Delivery: 1. Normal vaginal delivery   [   ] 
  2. Forceps / Ventouse         [   ] 
  3. Caesarean Section          [   ] 
     4. Not known        [   ] 
 
During First Pregnancy 
• High Blood Pressure only in pregnancy?  
Yes / No / Not known 
• Pre-eclampsia (High Blood pressure + ankle swelling 
+ protein in urine) Yes / No / Not known 
     Severe enough to have baby induced?   
Yes / No / Not known 
• Growth restriction  Yes / No / Not known 
     Severe enough to have baby induced?   
Yes / No / Not known 
• Protein in Urine  Yes / No / Not known 
• Blood Clots/Thrombosis Yes / No / Not known 
• Other medical problems in mother:____________ 
 
 
Drug exposure during First Pregnancy 
Please mark: Y = Yes or N = No or NK for Not known. 
If possible, please clarify if started by putting 1 and if stopped put 2 in relevant column 
Therapy At 
Conception 
First 
 13 weeks 
Weeks  
14 to 26 
More than 
26 weeks 
Breast-
feeding 
Hydroxychloroquine 
(Plaquenil) 
     
Steroids (Prednisolone)      
Azathioprine (Imuran)      
Cyclophosphamide       
Methotrexate      
Ciclosporin A (Neoral)      
Mycophenolate (CellCept)      
Aspirin      
Heparin (Clexane)      
Warfarin      
Antiepileptics  
(specify if possible) 
     
ACE Inhibitors 
(e.g. Lisinopril) 
     
Nifedipine / Amlodipine      
Labetalol      
Methyldopa      
Other or not known 
antihypertensives 
     
Folic Acid      
NSAIDs (eg Ibuprofen)      
Other Drugs 
(specify if possible) 
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LONG-TERM OUTCOMES IN SLE     	  
(Centre number: deleted) 
Study ID: Mother ID ____Child ID   _____    Gender:  F [   ]      M[   ] 
 
First 6 months: 
Neonatal Lupus Syndrome  Yes / No  
Congenital Heart Block   Yes / No 
Was the baby born with any 
abnormality    Yes / No 
Please specify _______________________ 
 
First 2 years: 
Developmental delay  Yes / No 
Special Needs    Yes / No  
Attention Deficit Disorder   Yes / No  
 
 
Outpatient Appointments  - First 2 Years 
 
Has your child ever attended an outpatient clinic?      Yes / No  
If yes, please tell us about the appointments at the outpatient clinics: 
Hospital Speciality and  
Consultant if known 
Disease or 
symptom 
Period of follow- 
up (months/years) 
    
    
    
    
    
 
Hospital admissions   
Has your child ever been admitted to hospital?     Yes / No 
If Yes, How many times? ________________  
Hospital Speciality and  
Consultant if known 
Disease or 
symptom 
Length of stay 
(days/weeks) 
    
    
    
    
    
 
Education   
Does your child have any special needs? (e.g. dyslexia)    Yes / No 
 
If yes, please state the special need: _________________________ 
PART B: CHILD 
1 
Immunisations	  received	  	  	  	  	  	  (Please	  circle	  as	  
appropriate)	  
BCG at birth (Asian babies)  Yes / No/Not known 
2, 3 and 4 months old 
Diphtheria  Yes / No/Not known 
Tetanus  Yes / No/Not known 
Pertussis  Yes / No/Not known 
	   (Whooping	  cough) 
Polio and Hib Yes / No/Not known 
MenC	  –	  Meningitis	  C Yes / No/Not known 
 
Around	  13	  mo ths	  old	  	  
   Measles, mumps and rubella (MMR) Yes/ No 
                        Or  Not known  
(NK) 
3 years & 4 months to 5 years old 
   DTP  Yes / No / NK  Polio Yes / No / NK 
 
13 to 18 years old 
   BCG   Yes / No / NK Diphtheria   Yes / No / NK 
   Polio Yes / No / NK Tetanu        Yes / No / NK 
DTP	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Drug exposure      Child ID: _________ 
 
We would like you to document as precisely as possible all prescribed medicines 
(excluding: calpol (paracetamol), antibiotics, and cough mixtures) received by your 
child in the following age groups: first two years, 2 to 5, 6 to 11, 12 to 16. With your 
permission, we would complete this information from your GP records but your 
feedback with this would be greatly appreciated. Put NK if Not Known. 
Age of child Name or 
type of drug 
(e.g. Carbamazepine, 
anti-epileptic) 
 
Duration of therapy (estimate) 
Up to 7 
days 
7 to 
30 days 
More than 1 month 
 
 
 
 
First 2 years 
 
 
    
 
 
 
2 to 5 years 
 
 
 
 
    
 
 
 
6 to 11 years 
 
 
 
 
    
 
 
 
12 to 16 years 
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